var title_f36_7_36976="Conjugated equine estrogens: Pediatric drug information";
var content_f36_7_36976=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"12\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Conjugated equine estrogens: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12624513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12644947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/29/22998?source=see_link\">",
"       Conjugated equine estrogens (systemic): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/30/14821?source=see_link\">",
"       Conjugated equine estrogens (topical): Pediatric drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13283 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-FF4A722CD6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_7_36976=[""].join("\n");
var outline_f36_7_36976=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/29/22998?source=related_link\">",
"      Conjugated equine estrogens (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/30/14821?source=related_link\">",
"      Conjugated equine estrogens (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_7_36977="Insertion of lever pessary";
var content_f36_7_36977=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F68708&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F68708&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Insertion of lever vaginal pessary",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 329px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Milex Products, Inc., Chicago, IL.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_7_36977=[""].join("\n");
var outline_f36_7_36977=null;
var title_f36_7_36978="Patient information: Low back pain in adults (The Basics)";
var content_f36_7_36978=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15460\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/51/4917\">",
"         Anatomy of the back",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?32/16/33026\">",
"         Patient information: Do I need imaging for low back pain? (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?40/62/41954\">",
"         Patient information: Herniated disc (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?39/44/40642\">",
"         Patient information: Spinal stenosis (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?21/51/22320\">",
"         Patient information: Back pain in children and adolescents (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?8/47/8950\">",
"         Patient information: Low back pain in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Low back pain in adults (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/low-back-pain-in-adults-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H480076093\">",
"      <span class=\"h1\">",
"       How worried should I be about low back pain?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Do not assume the worst. Almost everyone gets back pain at some point. Low back pain can be scary. But it is almost never serious. It usually goes away on its own. The cases that require surgery or urgent care are rare.",
"     </p>",
"     <p>",
"      See your doctor or nurse if you have back pain and you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have numbness or weakness in your legs",
"       </li>",
"       <li>",
"        Have problems with bowel or bladder control",
"       </li>",
"       <li>",
"        Have a fever or feel sick in other ways",
"       </li>",
"       <li>",
"        Take steroid medicine, such as",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?27/36/28230?source=see_link\">",
"         prednisone",
"        </a>",
"        , on a regular basis",
"       </li>",
"       <li>",
"        Have a history of cancer or osteoporosis",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You should also see a doctor if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Your back pain does not improve with rest or a change in position, and is so severe that you cannot perform simple tasks",
"       </li>",
"       <li>",
"        Your back pain does not start to improve within 3 to 4 weeks",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H480076100\">",
"      <span class=\"h1\">",
"       What are the parts of the back?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The back is made up of (",
"      <a class=\"graphic graphic_figure graphicRef56246 \" href=\"mobipreview.htm?4/51/4917\">",
"       figure 1",
"      </a>",
"      ):",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Vertebrae",
"        </strong>",
"        &ndash; A stack of bones that sit on top of one another like a stack of quarters. Each of these bones has a hole in the center. When stacked, the bones form a hollow tube that protects the spinal cord.",
"       </li>",
"       <li>",
"        <strong>",
"         Discs",
"        </strong>",
"        &ndash; Rubbery discs sit in between each of the vertebrae to add cushion and allow movement.",
"       </li>",
"       <li>",
"        <strong>",
"         Spinal cord and nerves",
"        </strong>",
"        &ndash; The spinal cord is the highway of nerves that connects the brain to the rest of the body. It runs through the vertebrae. Nerves branch from the spinal cord and pass in between the vertebrae. From there they connect to the arms, the legs, and the organs. (This is why problems in the back can cause leg pain or bladder problems.)",
"       </li>",
"       <li>",
"        <strong>",
"         Muscles, tendons, and ligaments",
"        </strong>",
"        &ndash; Together the muscles, tendons, and ligaments are called the \"soft tissues\" of the back. These soft tissues support the back and help hold it together.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H480076107\">",
"      <span class=\"h1\">",
"       What causes low back pain?",
"      </span>",
"      &nbsp;&mdash;&nbsp;In most cases, doctors and nurses do not know what causes low back pain. Pain can happen if you strain a muscle or hurt a tendon or ligament. But if that is the cause of your pain, doctors and nurses have no way of knowing it for sure. Pain can also happen if you have:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Damaged, bulging, or torn discs",
"       </li>",
"       <li>",
"        Arthritis affecting the joints of the spine",
"       </li>",
"       <li>",
"        Bony growths on the vertebrae that crowd nearby nerves",
"       </li>",
"       <li>",
"        A vertebra out of place",
"       </li>",
"       <li>",
"        A tumor or infection (but this is very rare)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H480076114\">",
"      <span class=\"h1\">",
"       Should I get an imaging test, like an MRI?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people do",
"      <strong>",
"       not",
"      </strong>",
"      need an imaging test. Most cases of back pain go away within 4 to 6 weeks &ndash; or in even less time. Doctors and nurses usually do not order imaging tests before then unless there are signs of something unusual.",
"     </p>",
"     <p>",
"      If your doctor or nurse does not order an imaging test, do not worry. He or she can still learn a lot about your pain just from looking you over and talking with you. Plus, treatment can start right away, even without an imaging test.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H480076121\">",
"      <span class=\"h1\">",
"       How can the doctor or nurse tell what is wrong just by talking to me?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your symptoms tell your doctor or nurse a lot about the cause of your pain. If your pain spreads down the back of one thigh, for instance, that could be a sign that one of the nerves that go to your leg is being pinched by a bulging or torn disc. If, on the other hand, your pain goes all the way down both legs, that could be a sign that you have bony growths on your spine.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H480076128\">",
"      <span class=\"h1\">",
"       What can I do to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The best thing you can do is to stay as active as possible &ndash; even if you are in pain. People with low back pain recover faster if they stay active. Walk as much as you can. If you stopped working because of your pain, try to get back to your normal routine soon. But do not overdo it.",
"     </p>",
"     <p>",
"      When you start to feel better, ask your doctor or nurse about exercises that can help strengthen your back. These exercises can help you get better faster and may make it less likely that you will have pain again.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H480076135\">",
"      <span class=\"h1\">",
"       How is back pain treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A small number of people end up needing surgery to treat back pain. But most people do well with simpler treatments, such as:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Pain medicines",
"        </strong>",
"        that you can get without a prescription. If these do not work, doctors and nurses can prescribe stronger pain medicines.",
"       </li>",
"       <li>",
"        <strong>",
"         Medicines to relax the muscles",
"        </strong>",
"        (called muscle relaxants)",
"       </li>",
"       <li>",
"        <strong>",
"         Injections",
"        </strong>",
"        of medicines that numb the back or reduce swelling",
"       </li>",
"       <li>",
"        <strong>",
"         Physical therapy",
"        </strong>",
"        to teach you special exercises and stretches",
"       </li>",
"       <li>",
"        <strong>",
"         Spinal manipulation",
"        </strong>",
"        , which is when someone like a physical therapist or a chiropractor moves or \"adjusts\" the joints of your back",
"       </li>",
"       <li>",
"        <strong>",
"         Acupuncture",
"        </strong>",
"        , which is when someone who knows traditional Chinese medicine inserts tiny needles into your body to block pain signals",
"       </li>",
"       <li>",
"        <strong>",
"         Massage",
"        </strong>",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H480076142\">",
"      <span class=\"h1\">",
"       What can I do to keep from getting back pain again?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Stay active and learn exercises that help strengthen and stretch your back. Learn to lift using your legs instead of your back. And avoid sitting or standing in the same position for too long.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H480076149\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/62/41954?source=see_link\">",
"       Patient information: Herniated disc (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/44/40642?source=see_link\">",
"       Patient information: Spinal stenosis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/16/33026?source=see_link\">",
"       Patient information: Do I need imaging for low back pain? (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/51/22320?source=see_link\">",
"       Patient information: Back pain in children and adolescents (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/47/8950?source=see_link\">",
"       Patient information: Low back pain in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?36/7/36978?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15460 Version 5.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.65.66-BC5B390E05-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_7_36978=[""].join("\n");
var outline_f36_7_36978=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H480076093\">",
"      How worried should I be about low back pain?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H480076100\">",
"      What are the parts of the back?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H480076107\">",
"      What causes low back pain?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H480076114\">",
"      Should I get an imaging test, like an MRI?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H480076121\">",
"      How can the doctor or nurse tell what is wrong just by talking to me?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H480076128\">",
"      What can I do to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H480076135\">",
"      How is back pain treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H480076142\">",
"      What can I do to keep from getting back pain again?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H480076149\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15460\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/51/4917\">",
"      Anatomy of the back",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/51/22320?source=related_link\">",
"      Patient information: Back pain in children and adolescents (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/16/33026?source=related_link\">",
"      Patient information: Do I need imaging for low back pain? (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/62/41954?source=related_link\">",
"      Patient information: Herniated disc (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/47/8950?source=related_link\">",
"      Patient information: Low back pain in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/44/40642?source=related_link\">",
"      Patient information: Spinal stenosis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_7_36979="Lumbar triangle of Petit";
var content_f36_7_36979=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F81616&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F81616&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 528px\">",
"   <div class=\"ttl\">",
"    Lumbar triangle of Petit",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 508px; height: 619px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_7_36979=[""].join("\n");
var outline_f36_7_36979=null;
var title_f36_7_36980="Fluvastatin: Patient drug information";
var content_f36_7_36980=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Fluvastatin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"     see \"Fluvastatin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/54/11111?source=see_link\">",
"     see \"Fluvastatin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F173506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lescol&reg;;",
"     </li>",
"     <li>",
"      Lescol&reg; XL",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F173507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Lescol&reg;;",
"     </li>",
"     <li>",
"      Lescol&reg; XL;",
"     </li>",
"     <li>",
"      Teva-Fluvastatin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10011779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691406",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower cholesterol and other harmful types of cholesterol in the body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691358",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower triglycerides.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691638",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to slow the progress of heart disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10011778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702154",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to fluvastatin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease or raised liver enzymes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10011783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696863",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take colestipol or cholestyramine within 4 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid or limit drinking wine, beer, or mixed drinks to less than 3 drinks a day. Drinking too much alcohol may raise your chance of liver disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10011784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698255",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698195",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Joint pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10011786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698663",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flu-like signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10011781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take in the evening.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10011782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10011787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10011788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12494 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-812927D4EA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_7_36980=[""].join("\n");
var outline_f36_7_36980=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173506\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173507\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011779\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011778\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011783\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011784\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011786\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011781\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011782\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011787\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011788\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=related_link\">",
"      Fluvastatin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/54/11111?source=related_link\">",
"      Fluvastatin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_7_36981="Tiotropium: Patient drug information";
var content_f36_7_36981=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Tiotropium: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"     see \"Tiotropium: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F228272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Spiriva&reg; HandiHaler&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F228273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Spiriva&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F14943895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691417",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to open the airways in lung diseases where spasm may cause breathing problems.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705187",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to tiotropium, atropine, ipratropium, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701034",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to milk, talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701052",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are having a breathing attack.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is not to be used to treat intense flare-ups of shortness of breath.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man with problems passing urine, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697312",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have myasthenia gravis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698350",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sore throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad nose irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698996",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Peak flow measurement low.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698964",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor right away if your normal dose does not work as well or if you need to use your inhaler more often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694186",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        Do not swallow capsule. The contents of the capsule will be breathed into the lungs.",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694582",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your puffer (inhaler) use checked with your doctor at each visit. Read and follow facts on how to use the puffer. Make sure you use the puffer the right way.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695566",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take the capsule out of the foil right before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695486",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Open dust cap by pulling up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695487",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Open mouthpiece by pulling up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695509",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put capsule in the chamber in the bottom of the puffer (inhaler).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694630",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Close mouthpiece until click is heard.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Leave dust cap open.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695539",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Press green piercing button once and let go.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695255",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep puffer (inhaler) at a level, upright position.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694848",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Breathe out fully. Never breathe out into the puffer (inhaler).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695515",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Place mouthpiece in your mouth. Close your lips around the mouthpiece.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696125",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and breathe in.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695100",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hold your breath as long as you can without harm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If any powder stays in the capsule, breathe out fully and repeat. When the capsule is empty, throw it away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695186",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are using more than 1 type of puffer (inhaler), ask your doctor which puffer to use first.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use a spacer with the puffer (inhaler).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696176",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use new puffer (inhaler) with each refill.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699370",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store capsules in the original container. Use right after opening.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11162 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-07C1274D5D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_7_36981=[""].join("\n");
var outline_f36_7_36981=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228272\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228273\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14943895\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028622\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028621\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028626\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028627\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028629\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028624\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028625\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028630\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028631\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=related_link\">",
"      Tiotropium: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_7_36982="Amobarbital: Drug information";
var content_f36_7_36982=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Amobarbital: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?31/53/32596?source=see_link\">",
"    see \"Amobarbital: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/17/43286?source=see_link\">",
"    see \"Amobarbital: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F134276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Amytal&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F134277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Amytal&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F134300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Barbiturate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F134280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypnotic:",
"     </b>",
"     I.M., I.V.: 65-200 mg at bedtime (maximum single dose: 1000 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sedative:",
"     </b>",
"     I.M., I.V.: 30-50 mg 2-3 times/day (maximum single dose: 1000 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      &ldquo;Amytal&reg; interview&rdquo; (unlabeled use):",
"     </b>",
"     I.V.: 50-100 mg/minute for total dose of 200-1000 mg or until patient experiences drowsiness, impaired attention, slurred speech, or nystagmus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Wada test (unlabeled use):",
"     </b>",
"     Intra-arterial: 100 mg over 4-5 seconds via percutaneous transfemoral catheter",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F134291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/17/43286?source=see_link\">",
"      see \"Amobarbital: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sedative:",
"     </b>",
"     I.M., I.V.: 6-12 years: Manufacturer's dosing range: 65-500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypnotic (unlabeled use):",
"     </b>",
"     I.M.: 2-3 mg/kg (maximum: 500 mg)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F2476742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F134281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosing should be reduced; specific recommendations not available.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F134282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosing should be reduced; specific recommendations not available.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F134255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as sodium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Amytal&reg;: 0.5 g",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F134239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F134302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-II",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F134258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.: Administer deeply into a large muscle. Do not use more than 5 mL at any single site (may cause tissue damage). I.M. dosages should not exceed 500 mg. Use 20% solution to facilitate larger doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Use only when I.M. administration is not feasible. Administer by slow I.V. injection (maximum: 50 mg/minute in adults).",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F134306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, D",
"     <sub>",
"      20",
"     </sub>",
"     W, LR, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Thiamine.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F134257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypnotic in short-term treatment of insomnia; reduce anxiety and provide sedation preoperatively",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F134297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic or diagnostic &ldquo;Amytal&reg; Interviewing&rdquo;; Wada test",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F13930080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F134298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined and is reported as barbiturate use (not specifically amobarbital).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, hypotension, syncope",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, anxiety, ataxia, confusion, CNS depression, dizziness, fever, hallucinations, headache, insomnia, nightmares, nervousness, psychiatric disturbances, somnolence, thinking abnormal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Megaloblastic anemia (following chronic phenobarbital use)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Liver damage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Hyperkinesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Apnea, atelectasis (postoperative), hypoventilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity reaction (including angioedema, rash, and exfoliative dermatitis)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F134261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to barbiturates or any component of the formulation; marked hepatic impairment; dyspnea or airway obstruction; porphyria",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F134243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Postmarketing studies have indicated that the use of hypnotic/sedative agents for sleep has been associated with hypersensitivity reactions including anaphylaxis as well as angioedema.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Paradoxical responses: May cause paradoxical responses, including agitation and hyperactivity, particularly in acute pain, chronic pain and pediatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sleep-related activities: An increased risk for hazardous sleep-related activities such as sleep-driving; cooking and eating food, and making phone calls while asleep has been noted with sedative-hypnotic medications. Discontinue treatment in patients who report a sleep-driving episode.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease; may cause hypotension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depression: Use with caution in patients with depression or suicidal tendencies.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment, decreased dosage may be needed; contraindicated in severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Insomnia: Appropriate use: When used as a hypnotic for the treatment of insomnia, effectiveness is limited to &le;2 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; decreased dosage may be needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use due to risk of overdose with low dosages, tolerance to sleep effects, and increased risk of physical dependence (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children &lt;6 years of age; use with caution in children &ge;6 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Alkaline solution: Solution for injection is highly alkaline and extravasation may cause local tissue damage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rapid administration: Rapid I.V. administration may cause respiratory depression, apnea, and hypotension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Gradual withdrawal is recommended if used over extended periods of time.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F134296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Induces",
"     </b>",
"     CYP2A6 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F134248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetaminophen: Barbiturates may increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Barbiturates may decrease the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Atenolol; Levobunolol; Metipranolol; Nadolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Barbiturates may increase the metabolism of Calcium Channel Blockers.  Management: Monitor for decreased therapeutic effects of calcium channel blockers with concomitant barbiturate therapy. Calcium channel blocker dose adjustments may be necessary. Nimodipine Canadian labeling contraindicates concomitant use with phenobarbital.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloramphenicol: Barbiturates may increase the metabolism of Chloramphenicol. Chloramphenicol may decrease the metabolism of Barbiturates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Barbiturates may diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible.  Management: Use of a non-hormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Barbiturates may diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.  Management: Use of alternative, nonhormonal contraceptives is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Barbiturates may decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Barbiturates may increase the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2A6 Substrates: CYP2A6 Inducers (Strong) may increase the metabolism of CYP2A6 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: Barbiturates may increase the metabolism of Disopyramide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May decrease the metabolism of Barbiturates. Barbiturates may decrease the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Doxycycline: Barbiturates may decrease the serum concentration of Doxycycline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etoposide: Barbiturates may decrease the serum concentration of Etoposide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etoposide Phosphate: Barbiturates may decrease the serum concentration of Etoposide Phosphate. Barbiturates may increase the metabolism, via CYP isoenzymes, of etoposide phosphate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felbamate: Barbiturates may decrease the serum concentration of Felbamate. Felbamate may increase the serum concentration of Barbiturates.  Management: Monitor for elevated barbiturate concentrations/toxicity if felbamate is initiated/dose increased, or reduced concentrations/effects if felbamate is discontinued/dose decreased. Refer to phenobarbital dosing guidelines for patients receiving that agent.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Barbiturates may enhance the CNS depressant effect of Fosphenytoin. Barbiturates may decrease the serum concentration of Fosphenytoin. Fosphenytoin may increase the serum concentration of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Griseofulvin: Barbiturates may decrease the serum concentration of Griseofulvin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of Barbiturates. Management: Consider a decrease in the barbiturate dose, as appropriate, when used together with hydroxyzine.  With concurrent use, monitor patients closely for excessive response to the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: Barbiturates may decrease the serum concentration of LamoTRIgine.  Management: See lamotrigine prescribing information for specific age-dependent dosing guidelines regarding concurrent use with a barbiturate, as well as for adjusting lamotrigine dosing if concurrent barbiturate therapy is discontinued.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meperidine: Barbiturates may enhance the CNS depressant effect of Meperidine. Barbiturates may increase serum concentrations of the active metabolite(s) of Meperidine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Barbiturates may enhance the CNS depressant effect of Methadone. Barbiturates may decrease the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May enhance the CNS depressant effect of Barbiturates. Barbiturates may decrease the serum concentration of Phenytoin. Phenytoin may increase the serum concentration of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: May enhance the adverse/toxic effect of Barbiturates. Primidone is converted to phenobarbital, and thus becomes additive with existing barbiturate therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: Barbiturates may decrease the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pyridoxine: May increase the metabolism of Barbiturates. Apparent in high pyridoxine doses (eg, 200 mg/day)",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Barbiturates may enhance the hepatotoxic effect of QuiNIDine. Barbiturates may decrease the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Teniposide: Barbiturates may decrease the serum concentration of Teniposide.  Management: Consider alternatives to combined treatment with barbiturates and teniposide due to the potential for decreased teniposide concentrations.  If the combination cannot be avoided, monitor teniposide response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Barbiturates may decrease the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Barbiturates may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Barbiturates may increase the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May decrease the metabolism of Barbiturates. Barbiturates may decrease the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Barbiturates may increase the metabolism of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: Barbiturates may decrease the serum concentration of Voriconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F134273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F134250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F134263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Barbiturates cross the placenta and distribute in fetal tissue. Teratogenic effects have been reported with 1st trimester exposure. Exposure during the 3rd trimester may lead to symptoms of acute withdrawal following delivery; symptoms may be delayed up to 14 days.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F134284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F134264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Small amounts of barbiturates are excreted in breast milk; information specific for amobarbital is not available.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Amytal Sodium Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (1): $690.25",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F134252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vital signs should be monitored during injection and for several hours after administration.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F134256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Therapeutic: 1-5 mcg/mL (SI: 4-22 micromole/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Toxic: &gt;10 mcg/mL (SI: &gt;44 micromole/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lethal: &gt;50 mcg/mL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F134265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Amybital (TW);",
"     </li>",
"     <li>",
"      Amycal (NO);",
"     </li>",
"     <li>",
"      Amytal Sodium (AU);",
"     </li>",
"     <li>",
"      Barbamyl (IL);",
"     </li>",
"     <li>",
"      Dorlotin (HU);",
"     </li>",
"     <li>",
"      Dorlotyn (HU);",
"     </li>",
"     <li>",
"      Eunoctal (FR);",
"     </li>",
"     <li>",
"      Isoamitil Sedante (ES);",
"     </li>",
"     <li>",
"      Isomytal (JP);",
"     </li>",
"     <li>",
"      Neur-Amyl (AU);",
"     </li>",
"     <li>",
"      Placidel (ES);",
"     </li>",
"     <li>",
"      Sodium Amytal (GB);",
"     </li>",
"     <li>",
"      Transital (ES)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F134242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Interferes with transmission of impulses from the thalamus to the cortex of the brain resulting in an imbalance in central inhibitory and facilitatory mechanisms",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F134260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: I.V.: Within 5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Readily crosses placenta; small amounts enter breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Primarily hepatic via microsomal enzymes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 15-40 hours (mean: 25 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine; feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/7/36982/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kavirajan H, &ldquo;The Amobarbital Interview Revisited: A Review of the Literature Since 1966,&rdquo;",
"      <i>",
"       Harv Rev Psychiatry",
"      </i>",
"      , 1999, 7(3):153-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/7/36982/abstract-text/10483934/pubmed\" id=\"10483934\" target=\"_blank\">",
"        10483934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8647 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-AD1D6AEAC5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_7_36982=[""].join("\n");
var outline_f36_7_36982=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134276\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134277\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134300\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134280\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134291\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2476742\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134281\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134282\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134255\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134239\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134302\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134258\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134306\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134257\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134297\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13930080\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134298\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134261\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134243\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134296\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134248\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134273\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134250\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134263\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134284\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134264\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322985\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134252\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134256\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134265\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134242\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134260\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8647\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8647|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?31/53/32596?source=related_link\">",
"      Amobarbital: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/17/43286?source=related_link\">",
"      Amobarbital: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_7_36983="Endometrial carcinoma: Histopathology and pathogenesis";
var content_f36_7_36983=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Endometrial carcinoma: Histopathology and pathogenesis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/7/36983/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/7/36983/contributors\">",
"     Lesley C Lomo, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/7/36983/contributors\">",
"     Jonathan L Hecht, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/7/36983/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/7/36983/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/7/36983/contributors\">",
"     Rochelle L Garcia, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/7/36983/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/7/36983/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/7/36983/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H766613\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer of the endometrium (lining of the uterus) is the most common gynecologic malignancy in developed countries and the second most common in developing countries (cervical cancer is more common) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36983/abstract/1\">",
"     1",
"    </a>",
"    ]. Endometrioid carcinoma is the common site and histologic subtype of endometrial carcinoma and of uterine cancer overall. Endometrioid tumors tend to have a favorable prognosis and typically present at an early stage with abnormal uterine bleeding. Other histologic types of endometrial carcinoma (eg, serous, clear cell) as well as other types of uterine cancer are associated with a poor prognosis. &nbsp;",
"   </p>",
"   <p>",
"    The histopathology and pathogenesis of endometrial carcinoma is reviewed here. An overview of endometrial carcinoma is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/7/21624?source=see_link\">",
"     \"Overview of endometrial carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9149782\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometrial carcinomas are classified into two major types (I and II), based upon light microscopic appearance, clinical behavior, and epidemiology. Most endometrial cancers (malignant neoplasms) are carcinomas. However, carcinosarcomas and other rare malignant neoplasms arise in the endometrium. This review focuses on endometrial carcinomas.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type I tumors include tumors of endometrioid histology that are grade 1 or 2; these comprise approximately 80 percent of endometrial carcinomas. These tumors typically have a favorable prognosis, are estrogen responsive, and may be preceded by an intraepithelial neoplasm (atypical",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      complex endometrial hyperplasia). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/58/26535?source=see_link&amp;anchor=H381678#H381678\">",
"       \"Classification and diagnosis of endometrial hyperplasia\", section on 'Risk of carcinoma'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Type II tumors account for 10 to 20 percent of endometrial carcinomas. They include grade 3 endometrioid tumors as well as tumors of non-endometrioid histology: serous, clear cell, mucinous, squamous, transitional cell, mesonephric, and undifferentiated. These tumors are often high-grade, have a poor prognosis, and are not clearly associated with estrogen stimulation. A precursor lesion is rarely identified. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/3/22584?source=see_link\">",
"       \"Type II endometrial carcinomas (eg, serous, clear cell, mucinous)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GROSS PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometrial carcinoma may be grossly visible as a single dominant mass within the endometrial cavity, may involve much of the endometrial cavity as friable neoplasm, or may be subtle or undetectable grossly as it diffusely replace the endometrium",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    myometrium. Gross examination of the uterus at the time of operation is frequently used to estimate depth of myometrial invasion in order to determine whether staging should be performed (ie, lymph node dissection). Gross evaluation is inherently difficult, however, particularly in uteri with extensive adenomyosis or distortion by leiomyomata. Although sometimes a frozen section is done to confirm depth of invasion, accuracy is limited by selection bias and frozen section interpretation difficulties. Final stage is assigned after more extensive examination of the uterus (",
"    <a class=\"graphic graphic_table graphicRef51307 \" href=\"mobipreview.htm?42/33/43549\">",
"     table 1",
"    </a>",
"    ). Staging of endometrial carcinoma is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/23/18810?source=see_link\">",
"     \"Endometrial carcinoma: Pretreatment evaluation, staging and surgical treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HISTOPATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histology of endometrial carcinomas is characterized according to the World Health Organization and the International Society of Gynecological Pathologists (",
"    <a class=\"graphic graphic_table graphicRef66649 \" href=\"mobipreview.htm?18/30/18923\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Endometrioid carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common type of endometrial carcinoma has endometrioid growth pattern (75 to 80 percent of cases). Most endometrioid adenocarcinomas are well-differentiated, gland forming neoplasms. Invasion is difficult to identify in the endometrium and back to back glands without intervening stroma or cribriform growth patterns are frequently used as surrogate markers of invasion (",
"    <a class=\"graphic graphic_picture graphicRef72034 \" href=\"mobipreview.htm?42/25/43415\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Endometrioid carcinomas are graded by using a combination of percent gland formation and nuclear grade. Grade 1 carcinomas have no more than 5 percent solid (nonglandular) growth. Grade 2 carcinomas have 6 to 50 percent solid growth. Grade 3 carcinomas have more than 50 percent solid growth. Squamous metaplasia (which can appear solid but typically is contained within glands) is not counted in determining percent solid growth. Bizarre nuclear atypia of neoplastic cells raises the grade by one (from 1 to 2 or 2 to 3).",
"   </p>",
"   <p>",
"    Molecular studies show that endometrioid neoplasms have a different genetic profile than nonendometrioid neoplasms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36983/abstract/2\">",
"     2",
"    </a>",
"    ]. Microsatellite instability and specific mutations of PTEN, K-ras, and beta-catenin genes are characteristic of endometrioid neoplasms, while p53 mutations predominate in nonendometrioid neoplasms.",
"   </p>",
"   <p>",
"    Variants of endometrioid carcinoma may be difficult to distinguish from high grade endometrioid and serous carcinoma. Endometrioid carcinoma with prominent squamous differentiation may be over graded due to mistaking squamous metaplasia for solid growth. So-called \"villoglandular\" growth may have a papillary growth pattern suggesting serous carcinoma, but villoglandular carcinoma lacks the cytologic features of serous carcinoma, including bizarre nuclei, scant cytoplasm, and nuclear stratification. These variants have the same prognosis as classic endometrioid carcinomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36983/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H101772148\">",
"    <span class=\"h2\">",
"     Serous and clear cell carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serous (",
"    <a class=\"graphic graphic_picture graphicRef63853 \" href=\"mobipreview.htm?7/11/7349\">",
"     picture 2",
"    </a>",
"    ) and clear cell (",
"    <a class=\"graphic graphic_picture graphicRef76599 \" href=\"mobipreview.htm?16/4/16458\">",
"     picture 3",
"    </a>",
"    ) carcinomas are highly aggressive neoplasms that commonly present at a more advanced stage then endometrioid carcinomas. Myometrial and vascular invasion are more common, and metastasis in the absence of these may occur. These subtypes account for 1 to 5 and 5 to 10 percent of endometrial carcinomas, respectively. Both are considered to be high grade and confer a poorer prognosis than endometrioid carcinomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36983/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serous carcinomas have complex papillary architecture, which resembles serous carcinoma of the ovary and always have marked nuclear atypia; psammoma bodies may be present.",
"   </p>",
"   <p>",
"    Clear cell carcinomas are characterized by tubulocystic, papillary, or solid patterns; unlike serous carcinomas, psammoma bodies are less commonly present. Cells cytoplasm is clear due to the presence of glycogen. Some pathologists require &ge;50 percent clear cell features to classify a neoplasm as a clear cell carcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36983/abstract/5\">",
"     5",
"    </a>",
"    ], while others use at least 25 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36983/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Myometrial invasion occurs in about 80 percent of clear cell carcinomas. From the standpoint of gene expression, they appear more similar to clear cell carcinomas arising in other organs (eg, the kidney) than to other uterine carcinomas including those of the serous variety [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36983/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Mixed pattern cancers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mixed carcinomas that contain both serous and endometrioid growth patterns may occur. If 50 percent or more of the carcinoma has a serous component, it is classified as serous; cases in which the serous component consists of more than 10 percent but less than 50 percent of the cancer are classified as mixed carcinomas. The prognosis of mixed carcinomas is controversial due to small study populations; approach to therapy should be cautious [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36983/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Rare subtypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mucinous, squamous cell, transitional cell, and small cell carcinomas comprise less than 2 percent of endometrial carcinomas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The molecular pathogenesis of endometrial carcinoma is specific to each histology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Endometrioid histology (type I carcinoma)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometrioid histology is associated with unopposed estrogen, endometrial hyperplasia (intraepithelial neoplasia), and younger patient age. These carcinomas are thought to be caused by a combination of hormonal factors and mutational events. Gene expression in endometrial epithelium varies with the hormonal milieu [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36983/abstract/12\">",
"     12",
"    </a>",
"    ]; the genes that are most commonly expressed in secretory endometrium are present in low levels in endometrial carcinomas. From the standpoint of gene expression profiling, these neoplasms resemble proliferative, more than secretory, epithelium. This may explain, in part, the anti-neoplastic effect of progestins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36983/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The common genetic abnormalities identified in endometrioid neoplasms (intraepithelial",
"    <span class=\"nowrap\">",
"     neoplasm/hyperplasia",
"    </span>",
"    and endometrioid carcinoma) include microsatellite instability, K-ras and PTEN mutations, and defects in DNA mismatch repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36983/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. p53 mutations are infrequent; they occur late in the development of type I neoplasms and early in type II neoplasms (see below), and may partially account for the different rates of progression of these two subtypes of endometrial carcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36983/abstract/15\">",
"     15",
"    </a>",
"    ]. Clinical applications of discoveries in the field of epigenetics may become important in endometrial carcinoma prevention, diagnosis, and treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36983/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     PTEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Loss of PTEN function (through mutation or deletion) appears to be an early event in carcinogenesis of endometrioid endometrial adenocarcinomas; this suggests a possible \"gatekeeper\" role for this gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36983/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. As an example, a study of normal, intraepithelial neoplasms (complex atypical",
"    <span class=\"nowrap\">",
"     hyperplasia/&rdquo;pre-cancer&rdquo;)",
"    </span>",
"    and endometrioid carcinomas using computerized morphometry found PTEN mutation rates of 0, 55, and 83 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36983/abstract/19\">",
"     19",
"    </a>",
"    ]. The authors also observed scattered loss of PTEN protein expression in normal endometrium exposed to protracted unopposed estrogen, which increases with age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36983/abstract/20\">",
"     20",
"    </a>",
"    ]. By comparison, neoplastic (whether invasive or not) endometrium contained contiguous groups of PTEN protein-negative glands. PTEN mutations may also be of prognostic significance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/23/18810?source=see_link\">",
"     \"Endometrial carcinoma: Pretreatment evaluation, staging and surgical treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Microsatellite instability",
"    </span>",
"    &nbsp;&mdash;&nbsp;About 20 percent of sporadic endometrioid endometrial carcinomas of all grades demonstrate a molecular phenotype referred to as microsatellite instability (MSI). Microsatellites are short segments of repetitive DNA bases that are scattered throughout the genome; they are found predominantly in non-coding DNA. MSI is the propensity to develop changes in the number of repeat elements as compared with normal tissue due to DNA repair errors made during replication. MSI is rare (&lt;5 percent) in nonendometrioid endometrial cancers, where the primary genetic defect is in the p53 gene and genetic instability is manifest globally at the chromosomal, rather than the microsatellite, level.",
"   </p>",
"   <p>",
"    MSI can be observed in intraepithelial neoplasms",
"    <span class=\"nowrap\">",
"     (complex/atypical",
"    </span>",
"    hyperplasia) and is an early event in carcinogenesis due to inactivation of intranuclear proteins of the \"DNA mismatch repair system\" (ie, MSH-2, MLH-1, and MSH-6). This defect is also seen in patients with colon carcinoma due to Hereditary Non-Polyposis Colorectal Cancer Syndrome (HNPCC). MLH-1 inactivation is the most common event and is accomplished by hypermethylation of CpG islands in the gene promoter, a process known as epigenetic silencing. This mechanism is different from that in colon carcinoma where MSI is due to mutations in the MSH-2, MLH-1, and MSH-6 genes. Inherited or somatically acquired mutations of MSH-6, another mismatch repair element, are also common in patients with MSI associated endometrial carcinomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36983/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Nonendometrioid histology (type II neoplasms)",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to type I neoplasms, type II neoplasms are commonly associated with p53 mutations, resulting in abnormal accumulation of the p53 protein and high Ki-67 labeling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36983/abstract/14,21\">",
"     14,21",
"    </a>",
"    ]. Other contrasting features of type II neoplasms are a nondiploid karyotype and",
"    <span class=\"nowrap\">",
"     HER-2/neu",
"    </span>",
"    (c-erbB-2) overexpression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36983/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H101772155\">",
"    <span class=\"h2\">",
"     Serous carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serous carcinomas are believed to develop from \"endometrial intraepithelial carcinoma\" (EIC), a lesion related to neoplastic transformation of the endometrial surface epithelium (such as a benign endometrial polyp), against a background of endometrial atrophy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36983/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Clear cell carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;No proven precursor lesions or epidemiologic risk factors for clear cell carcinoma have been identified. A putative precursor lesion has been proposed, but further confirmatory studies are needed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36983/abstract/23\">",
"     23",
"    </a>",
"    ]. Rare cases of intraepithelial neoplasm with clear cell morphology have been seen by one contributor (RG).",
"   </p>",
"   <p>",
"    These carcinomas have a distinctive pattern by gene expression profile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36983/abstract/8\">",
"     8",
"    </a>",
"    ]. They generally do not express estrogen and progesterone receptors, and in contrast to serous carcinomas, they are negative for p53 mutations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Biomarkers related to therapy and outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several biologic markers correlate with prognosis, although they are less important predictors of prognosis than stage and are not typically used in clinical practice. Unfavorable markers include mutation and consequent overexpression of p53, high proliferation index (ie, increased staining for",
"    <span class=\"nowrap\">",
"     MIB-1/Ki-67),",
"    </span>",
"    abnormal DNA ploidy, and increased S-phase fraction, DNA methylation, or expression of p21. Favorable indicators include preserved expression of estrogen and progesterone receptors.",
"   </p>",
"   <p>",
"    There is growing interest in the relevance of targeted biologic therapies for treating endometrial carcinoma. Targets of current interest include epidermal growth factor receptor (EGFR),",
"    <span class=\"nowrap\">",
"     HER-2/neu,",
"    </span>",
"    and Estrogen and Progesterone Receptor",
"    <span class=\"nowrap\">",
"     (ER/PR).",
"    </span>",
"    Expression levels in endometrial carcinomas have been reported as follows: EGFR (49 percent),",
"    <span class=\"nowrap\">",
"     HER-2/neu",
"    </span>",
"    (59 percent), ER (67 percent), PR (71 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     EGFR expression",
"    </span>",
"    &nbsp;&mdash;&nbsp;EGFR expression correlates with nonendometrioid histology and metastases at time of diagnosis. For patients with endometrioid histology, EGFR predicts a reduction in survival from 89 to 69 percent; for serous and clear cell histology, EGFR predicts a reduction in survival from 86 to 27 percent",
"    <span class=\"nowrap\">",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?36/7/36983/abstract/24\">",
"      24",
"     </a>",
"     ].",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     HER-2/neu overexpression",
"    </span>",
"    &nbsp;&mdash;&nbsp;HER-2/neu",
"    overexpression is associated with nonendometrioid histology, higher grade, older age, and depth of myometrial invasion, but is not an independent predictor of prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36983/abstract/25\">",
"     25",
"    </a>",
"    ]. Success using herceptin for recurrent or metastatic disease has only appeared in case reports and is not a standard practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36983/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     ER and PR expression",
"    </span>",
"    &nbsp;&mdash;&nbsp;ER and PR expression typically occur together and vary by histologic type. Carcinomas with endometrioid histology express both proteins in 92 percent of cases, with decreasing expression at higher grade. Carcinomas with serous histology express ER in 31 percent of cases and PR in 12 percent. Clear cell histology rarely expresses either protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36983/abstract/27-30\">",
"     27-30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PATHOLOGIC FEATURES AFFECTING PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several non-staging pathologic features may affect treatment and management of endometrial carcinoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Carcinoma involving an endometrial polyp",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Serous carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;These carcinomas have been historically considered to be aggressive neoplasms even when there is no myometrial invasion (eg, confined to the endometrium or confined to the surface of an endometrial polyp). Patients with so-called \"minimal uterine serous carcinoma\", \"intraepithelial serous carcinoma\", or \"endometrial intraepithelial carcinoma\" require a full staging procedure to determine prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36983/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Interestingly, some data suggest that properly staged patients with stage IA serous carcinoma and no residual disease at hysterectomy have a good prognosis, with no recurrence at up to 170 months follow-up (median: 38 months), regardless of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36983/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Endometrioid carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometrioid carcinoma confined to a polyp should be considered to be carcinoma without myometrial invasion (stage pT1a). Such carcinomas have an excellent prognosis and low risk of lymph node metastasis; thus, extensive staging (eg, lymph node dissection) or follow-up is generally not performed. It is unclear whether a biopsy specimen is an adequate sample for the diagnosis of \"cancer confined to polyp\". Polypectomy specimens or office biopsies without endometrial curettings may underestimate the true extent of disease in other areas of the uterus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36983/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The coincidence of endometrial carcinoma in a polyp does not imply that endometrial polyps are premalignant. Their association is due to the fact that endometrial polyps, carcinoma and cancer precursors (endometrial intraepithelial neoplasia) arise in the setting of persistent estrogen exposure (anovulatory cycles or obesity). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/10/7336?source=see_link\">",
"     \"Endometrial polyps\"",
"    </a>",
"    and",
"    <span class=\"nowrap\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/58/26535?source=see_link\">",
"      \"Classification and diagnosis of endometrial hyperplasia\"",
"     </a>",
"     .)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Pelvic/peritoneal washing cytology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic/peritoneal",
"    washing cytology is a way of assessing microscopic peritoneal spread. In a minority of patients, positive washings are the only evidence of neoplasm outside the endometrium. It is thought that such spread is due to retrograde migration of neoplastic cells through the fallopian tube; however, most clinicians will not change management based on positive peritoneal wash; that practice is reflected in most recent staging.",
"   </p>",
"   <p>",
"    It has not been established that positive cytology without other evidence of extra-uterine disease (ie, carcinoma in lymph nodes or biopsies) or other high risk factors (ie, high grade, lymphovascular invasion, or deep myometrial invasion) indicates an increased risk of recurrence. Because of this uncertainty, the use of adjuvant treatment in these women is controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36983/abstract/35-37\">",
"     35-37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Lymphatic or blood vessel invasion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphatic or blood vessel invasion (LVI) is not part of the formal staging system of endometrial carcinomas and is most often seen in high stage (node positive) disease. Thus, when lymph node sampling is not performed, LVI may prompt either additional investigations or additional therapy.",
"   </p>",
"   <p>",
"    LVI is less prognostically significant in well-staged, early (node-negative) disease. Although associated with deep myometrial invasion (stage pT1c), high grade or nonendometrioid histology, and tumor size greater than 2 cm, LVI is not an independent predictor of distant failure and death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36983/abstract/38\">",
"     38",
"    </a>",
"    ]. This likely reflects the fact that one neoplasm has invaded (past its compartment, past the basement membrane), it has access to lymph (extracellular fluid) and may metastasis whether or not it is seen in preformed spaces",
"    <span class=\"nowrap\">",
"     (lymphatics/vessels).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Alternate grading schemes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most pathologists still use the FIGO grading for cancers with endometrioid histology. However, several two-tiered or binary grading schemes have been proposed to increase interobserver reproducibility and bypass histologic features that can be difficult to assess (recognition of small amounts of solid growth, distinction of squamous from non-squamous solid growth, and assessment of degree of nuclear atypia). Studies have not shown prognostic advantage over FIGO, even when the system is condensed into a binary system (FIGO grades 1 and 2 versus grade 3) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36983/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?18/55/19314?source=see_link\">",
"       \"Patient information: Endometrial cancer diagnosis and staging (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/12/8388?source=see_link\">",
"       \"Patient information: Endometrial cancer treatment after surgery (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endometrial carcinomas are classified as type I or II (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Histopathology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Pathogenesis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Type I endometrial carcinomas (70 to 80 percent of cases) have endometrioid histology, are associated with unopposed estrogen exposure, and are often preceded by intraepithelial neoplasm. Common genetic alterations include microsatellite instability and specific mutations of PTEN, K-ras, and beta-catenin genes.",
"     </li>",
"     <li>",
"      Type II endometrial carcinomas have nonendometrioid histology (usually serous or clear cell) with an aggressive clinical course. Hormonal risk factors have not been identified and there is rarely identified intraepithelial precursor. p53 mutations are the predominate molecular finding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stage of disease is the primary determinant of prognosis and therapy. Nonstaging pathologic features that may affect treatment and management include (see",
"      <a class=\"local\" href=\"#H19\">",
"       'Pathologic features affecting prognosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Biomarkers related to therapy and outcome'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Carcinoma confined to an endometrial polyp",
"     </li>",
"     <li>",
"      Positive",
"      <span class=\"nowrap\">",
"       pelvic/peritoneal",
"      </span>",
"      washing cytology is an otherwise low risk carcinoma",
"     </li>",
"     <li>",
"      Lymphatic or blood vessel invasion",
"     </li>",
"     <li>",
"      Expression of",
"      <span class=\"nowrap\">",
"       Estrogen/Progesterone",
"      </span>",
"      receptors, EGFR,",
"      <span class=\"nowrap\">",
"       Her-2/neu",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36983/abstract/1\">",
"      Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36983/abstract/2\">",
"      Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 2006; 24:4783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36983/abstract/3\">",
"      Zaino RJ, Kurman RJ, Brunetto VL, et al. Villoglandular adenocarcinoma of the endometrium: a clinicopathologic study of 61 cases: a gynecologic oncology group study. Am J Surg Pathol 1998; 22:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36983/abstract/4\">",
"      Boruta DM 2nd, Gehrig PA, Groben PA, et al. Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference? Cancer 2004; 101:2214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36983/abstract/5\">",
"      Christopherson WM, Alberhasky RC, Connelly PJ. Carcinoma of the endometrium: I. A clinicopathologic study of clear-cell carcinoma and secretory carcinoma. Cancer 1982; 49:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36983/abstract/6\">",
"      Murphy KT, Rotmensch J, Yamada SD, Mundt AJ. Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys 2003; 55:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36983/abstract/7\">",
"      Cirisano FD Jr, Robboy SJ, Dodge RK, et al. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. Gynecol Oncol 2000; 77:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36983/abstract/8\">",
"      Zorn KK, Bonome T, Gangi L, et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 2005; 11:6422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36983/abstract/9\">",
"      Williams KE, Waters ED, Woolas RP, et al. Mixed serous-endometrioid carcinoma of the uterus: pathologic and cytopathologic analysis of a high-risk endometrial carcinoma. Int J Gynecol Cancer 1994; 4:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36983/abstract/10\">",
"      Tornos C, Silva EG, Khorana SM, Burke TW. High-stage endometrioid carcinoma of the ovary. Prognostic significance of pure versus mixed histologic types. Am J Surg Pathol 1994; 18:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36983/abstract/11\">",
"      Carcangiu ML, Chambers JT. Uterine papillary serous carcinoma: a study on 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian carcinoma. Gynecol Oncol 1992; 47:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36983/abstract/12\">",
"      Mutter GL, Lin MC, Fitzgerald JT, et al. Changes in endometrial PTEN expression throughout the human menstrual cycle. J Clin Endocrinol Metab 2000; 85:2334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36983/abstract/13\">",
"      Mutter GL, Baak JP, Fitzgerald JT, et al. Global expression changes of constitutive and hormonally regulated genes during endometrial neoplastic transformation. Gynecol Oncol 2001; 83:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36983/abstract/14\">",
"      Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol 2000; 13:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36983/abstract/15\">",
"      Lax SF, Kurman RJ. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses. Verh Dtsch Ges Pathol 1997; 81:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36983/abstract/16\">",
"      Bussaglia E, del Rio E, Matias-Guiu X, Prat J. PTEN mutations in endometrial carcinomas: a molecular and clinicopathologic analysis of 38 cases. Hum Pathol 2000; 31:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36983/abstract/17\">",
"      Zhou XC, Dowdy SC, Podratz KC, Jiang SW. Epigenetic considerations for endometrial cancer prevention, diagnosis and treatment. Gynecol Oncol 2007; 107:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36983/abstract/18\">",
"      Kinzler KW, Vogelstein B. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 1997; 386:761, 763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36983/abstract/19\">",
"      Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000; 92:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36983/abstract/20\">",
"      Mutter GL, Ince TA, Baak JP, et al. Molecular identification of latent precancers in histologically normal endometrium. Cancer Res 2001; 61:4311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36983/abstract/21\">",
"      Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch 2004; 444:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36983/abstract/22\">",
"      Amant F, Moerman P, Neven P, et al. Endometrial cancer. Lancet 2005; 366:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36983/abstract/23\">",
"      Fadare O, Liang SX, Ulukus EC, et al. Precursors of endometrial clear cell carcinoma. Am J Surg Pathol 2006; 30:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36983/abstract/24\">",
"      Khalifa MA, Mannel RS, Haraway SD, et al. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas. Gynecol Oncol 1994; 53:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36983/abstract/25\">",
"      Peir&oacute; G, Mayr D, Hillemanns P, et al. Analysis of HER-2/neu amplification in endometrial carcinoma by chromogenic in situ hybridization. Correlation with fluorescence in situ hybridization, HER-2/neu, p53 and Ki-67 protein expression, and outcome. Mod Pathol 2004; 17:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36983/abstract/26\">",
"      Grushko TA, Filiaci VL, Mundt AJ, et al. An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2008; 108:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36983/abstract/27\">",
"      Niikura H, Sasano H, Kaga K, et al. Expression of epidermal growth factor family proteins and epidermal growth factor receptor in human endometrium. Hum Pathol 1996; 27:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36983/abstract/28\">",
"      Kounelis S, Kapranos N, Kouri E, et al. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature. Mod Pathol 2000; 13:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36983/abstract/29\">",
"      Lax SF, Pizer ES, Ronnett BM, Kurman RJ. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. Hum Pathol 1998; 29:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36983/abstract/30\">",
"      Darvishian F, Hummer AJ, Thaler HT, et al. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases. Am J Surg Pathol 2004; 28:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36983/abstract/31\">",
"      Hui P, Kelly M, O'Malley DM, et al. Minimal uterine serous carcinoma: a clinicopathological study of 40 cases. Mod Pathol 2005; 18:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36983/abstract/32\">",
"      Wheeler DT, Bell KA, Kurman RJ, Sherman ME. Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation. Am J Surg Pathol 2000; 24:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36983/abstract/33\">",
"      Kelly MG, O'malley DM, Hui P, et al. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecol Oncol 2005; 98:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36983/abstract/34\">",
"      Mittal K, Da Costa D. Endometrial hyperplasia and carcinoma in endometrial polyps: clinicopathologic and follow-up findings. Int J Gynecol Pathol 2008; 27:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36983/abstract/35\">",
"      Kadar N, Homesley HD, Malfetano JH. Positive peritoneal cytology is an adverse factor in endometrial carcinoma only if there is other evidence of extrauterine disease. Gynecol Oncol 1992; 46:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36983/abstract/36\">",
"      Fadare O, Mariappan MR, Hileeto D, et al. Upstaging based solely on positive peritoneal washing does not affect outcome in endometrial cancer. Mod Pathol 2005; 18:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36983/abstract/37\">",
"      Morrow CP, Bundy BN, Kurman RJ, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1991; 40:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36983/abstract/38\">",
"      Mariani A, Webb MJ, Keeney GL, et al. Surgical stage I endometrial cancer: predictors of distant failure and death. Gynecol Oncol 2002; 87:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36983/abstract/39\">",
"      Scholten AN, Smit VT, Beerman H, et al. Prognostic significance and interobserver variability of histologic grading systems for endometrial carcinoma. Cancer 2004; 100:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36983/abstract/40\">",
"      Alkushi A, Abdul-Rahman ZH, Lim P, et al. Description of a novel system for grading of endometrial carcinoma and comparison with existing grading systems. Am J Surg Pathol 2005; 29:295.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3192 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-484BBBCA60-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_7_36983=[""].join("\n");
var outline_f36_7_36983=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H766613\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9149782\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GROSS PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HISTOPATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Endometrioid carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H101772148\">",
"      Serous and clear cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Mixed pattern cancers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Rare subtypes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Endometrioid histology (type I carcinoma)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - PTEN",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Microsatellite instability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Nonendometrioid histology (type II neoplasms)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H101772155\">",
"      Serous carcinoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Clear cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Biomarkers related to therapy and outcome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - EGFR expression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - HER-2/neu overexpression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - ER and PR expression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PATHOLOGIC FEATURES AFFECTING PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Carcinoma involving an endometrial polyp",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Serous carcinoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Endometrioid carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Pelvic/peritoneal washing cytology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Lymphatic or blood vessel invasion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Alternate grading schemes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3192\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3192|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/25/43415\" title=\"picture 1\">",
"      Endometrioid cancer histolo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?7/11/7349\" title=\"picture 2\">",
"      Serous cancer histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?16/4/16458\" title=\"picture 3\">",
"      Clear cell cancer histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3192|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/33/43549\" title=\"table 1\">",
"      Staging uterine carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/30/18923\" title=\"table 2\">",
"      Histology endometrial cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/58/26535?source=related_link\">",
"      Classification and diagnosis of endometrial hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/23/18810?source=related_link\">",
"      Endometrial carcinoma: Pretreatment evaluation, staging and surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/10/7336?source=related_link\">",
"      Endometrial polyps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/7/21624?source=related_link\">",
"      Overview of endometrial carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?18/55/19314?source=related_link\">",
"      Patient information: Endometrial cancer diagnosis and staging (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/12/8388?source=related_link\">",
"      Patient information: Endometrial cancer treatment after surgery (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/3/22584?source=related_link\">",
"      Type II endometrial carcinomas (eg, serous, clear cell, mucinous)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_7_36984="Salmonellosis risk factors";
var content_f36_7_36984=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F80734&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F80734&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 579px\">",
"   <div class=\"ttl\">",
"    Pathogenic bacterial properties and host factors conferring increased susceptibility to Salmonella infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 559px; height: 508px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Infections of the Gastrointestinal Tract, Blaser, Smith, Ravdin, et al (Eds), Lippincott Williams &amp; Wilkins, Phildadelphia 1995. Copyright &copy; 1995 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_7_36984=[""].join("\n");
var outline_f36_7_36984=null;
var title_f36_7_36985="Comorbid problems associated with multiple sclerosis in adults";
var content_f36_7_36985=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Comorbid problems associated with multiple sclerosis in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/7/36985/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/7/36985/contributors\">",
"     Michael J Olek, DO",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/7/36985/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/7/36985/contributors\">",
"     Francisco Gonzalez-Scarano, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/7/36985/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/7/36985/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/7/36985/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple sclerosis (MS) is an autoimmune inflammatory demyelinating disease of the central nervous system (CNS) that is a leading cause of disability in young adults.",
"   </p>",
"   <p>",
"    A range of symptomatic problems can occur in patients with MS. Cognitive dysfunction, depression, fatigue, and mood swings are increasingly common with disease progression. Spasticity, tremor, seizures, sphincter dysfunction, and sexual dysfunction may also complicate disease progression.",
"   </p>",
"   <p>",
"    Management of the comorbid problems associated with MS will be reviewed here. Other aspects of MS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32458?source=see_link\">",
"     \"Epidemiology and clinical features of multiple sclerosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35130?source=see_link\">",
"     \"Diagnosis of multiple sclerosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/7/41082?source=see_link\">",
"     \"Treatment of relapsing-remitting multiple sclerosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/41/26265?source=see_link\">",
"     \"Treatment of progressive multiple sclerosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     COGNITIVE DYSFUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Frank dementia is an uncommon feature of MS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/1\">",
"     1",
"    </a>",
"    ], occurring in less than 5 percent of patients. It is usually only encountered in severely affected individuals. However, 43 to 70 percent of patients have cognitive impairment on the basis of neuropsychological testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/2\">",
"     2",
"    </a>",
"    ]. The prevalence of cortical syndromes such as aphasia, apraxia, and agnosia is low.",
"   </p>",
"   <p>",
"    Cognitive impairment may be common even at the onset of MS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The most frequent abnormalities are with abstract conceptualization, recent memory, attention, and speed of information processing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Different disease courses may have different cognitive profiles. As an example, one study found that patients with relapsing-remitting MS generally had better cognitive performance than patients with progressive types of MS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The degree of cognitive decline in patients with MS correlates with the severity of cerebral pathology on MRI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/4,7-10\">",
"     4,7-10",
"    </a>",
"    ]. Furthermore, cortical atrophy on as measured by MRI correlates with cognitive impairment, suggesting that gray as well as white matter atrophy may contribute to the cognitive decline in patients with MS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/11-15\">",
"     11-15",
"    </a>",
"    ]. In addition to neuropathology, a number of other factors are implicated in disturbed cognitive functioning in MS patients, including depression.",
"   </p>",
"   <p>",
"    Acute cerebral lesions occasionally manifest as a confusional state associated with progressive focal paralysis. These findings can be mistakenly attributed to a tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A neuropsychological screening battery is a valuable screening test for cognitive dysfunction in patients with chronic-progressive MS; impairment correlates with the lesion burden on MRI as well as with atrophy of the corpus callosum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Impact of depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depression frequently has a negative impact on cognition, particularly on memory, attention, and concentration. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Depression'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Depression, lack of social support, and the presence of cognitive impairment have been shown to correlate with one another, independent of level of physical disability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/17\">",
"     17",
"    </a>",
"    ]. Depression is also correlated with use of less effective coping styles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/18\">",
"     18",
"    </a>",
"    ]. These relationships are likely quite complex and interactive.",
"   </p>",
"   <p>",
"    The ability of severe clinical depression to reduce performance on neuropsychological measures is well established in healthy controls and in patients with known risk factors for cognitive dysfunction, such as those with traumatic brain injury. In patients with MS, a number of cognitive domains related to executive functioning may be especially vulnerable to depression. These domains include working memory, planning ability, information processing speed, and nonspeeded central executive skill [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/19-23\">",
"     19-23",
"    </a>",
"    ]. Thus, depression likely contributes to cognitive dysfunction in patients with MS, which in turn leads to impaired problem solving and poor coping in real world situations, where people frequently need to be able to make flexible and instantaneous coping choices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pharmacologic treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no proven therapies for the treatment of cognitive impairment related to MS, although disease-modifying agents for MS and cholinesterase inhibitors have been examined in the hope that they would have a beneficial impact on cognitive function. The treatment of depression and pain may have some impact on the patient's experience of cognitive dysfunction. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Depression'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Disease modifying therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although data are limited, some of the current disease modifying medications, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/10/8358?source=see_link\">",
"     interferon beta-1a",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/13/16597?source=see_link\">",
"     interferon beta-1b",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/11/26806?source=see_link\">",
"     fingolimod",
"    </a>",
"    , may slow the progression of cognitive dysfunction in MS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/24\">",
"     24",
"    </a>",
"    ]. Randomized trials have established the efficacy of these drugs for reducing relapse rates and improving surrogate measures such as MRI outcomes in patients with relapsing form of MS (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/7/41082?source=see_link\">",
"     \"Treatment of relapsing-remitting multiple sclerosis in adults\"",
"    </a>",
"    ). However, these trials did not routinely evaluate cognitive outcomes, and results were inconsistent in the trials that did [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/24\">",
"     24",
"    </a>",
"    ]. Much of the data suggesting benefit for cognitive outcomes are from studies with methodologic limitations including small sample size, open-label design, or lack of a control group. Therefore, the impact of these disease-modifying therapies on cognitive impairment in MS remains uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Cholinesterase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholinesterase inhibitors were initially developed as treatment for patients with Alzheimer disease, a condition associated with a cholinergic deficit in the cortex. There is no known cholinergic deficit associated with MS. Although one small trial suggested that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/30/10726?source=see_link\">",
"     donepezil",
"    </a>",
"    was modestly beneficial for the treatment of cognitive decline in MS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/25\">",
"     25",
"    </a>",
"    ], later trials found no benefit for cholinesterase inhibitors compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Nonpharmacologic approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonpharmacologic approaches to the treatment of cognitive deficits in patients with MS consist primarily of support and improvement of coping strategies, particularly because the benefits of medication and rehabilitation are fairly limited. Thus, the most common strategies for managing cognitive difficulties associated with MS require the patient to compensate for these problems and to accommodate them when unable to compensate. A fair amount of assistance from family members, friends, co-workers, and caregivers is frequently needed to enable the patient to compensate and accommodate. As an example, patients often need assistance to maintain a clean and organized home environment.",
"   </p>",
"   <p>",
"    There are a number of strategies that may be useful for managing specific types of cognitive problems.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The use of personal organizers, particularly those with alarms, can be helpful for patients who have difficulty with memory and organization. Written reminders, directions, and phone logs can serve the same purpose.",
"     </li>",
"     <li>",
"      Pacing of activities to manage physical and cognitive fatigue can be quite helpful. For patients who wish to keep working outside the home, appropriate pacing can be crucial.",
"     </li>",
"     <li>",
"      Accommodations such as telecommuting and job sharing that allow the person with MS adequate opportunities to rest can help keep patients productive in the work force.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cognitive rehabilitation techniques are another approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/28\">",
"     28",
"    </a>",
"    ], but data related to clinical application of these methods are limited. A 2011 systematic review and meta-analysis identified 14 studies of cognitive training or cognitive-behavioral interventions in a total of 770 patients with MS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/29\">",
"     29",
"    </a>",
"    ]. Cognitive training was computer-assisted in nine studies, and in six others was combined with compensatory strategies including external aids such as calendars, diaries, notebooks, and lists, or internal aids such as visualization and semantic categorization. The overall quality of the included studies was low or very low due to methodologic limitations, and there was marked heterogeneity of outcome measures. The following observations were reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/29\">",
"     29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cognitive training combined with other neuropsychologic rehabilitation methods did",
"      <strong>",
"       not",
"      </strong>",
"      lead to statistically significant improvement for most outcomes, including attention, information processing speed, executive function, verbal and visual functions, mood, fatigue, personality, anxiety, or quality of life",
"     </li>",
"     <li>",
"      Cognitive training did have statistically significant benefit for three subcategories of cognitive performance, which were memory span, working memory, and immediate visual memory",
"     </li>",
"     <li>",
"      Despite mostly negative results from the meta-analyses of the pooled data, some evidence of benefit was noted in 12 of the 14 included studies when analyzed individually",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further research into the application of cognitive rehabilitation techniques is clearly needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DEPRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cross-sectional studies have shown some degree of affective disturbance in up to two-thirds of patients with MS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/30\">",
"     30",
"    </a>",
"    ]. Depression is the most common manifestation; it occurs in part due to the burden of having to cope with a chronic, incurable disease. Euphoria is usually associated with moderate or severe mental impairment. Patients may also manifest a dysphoric state with swings from depression to elation.",
"   </p>",
"   <p>",
"    Depression may be more common in patients with MS than in others with chronic medical conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/18,31\">",
"     18,31",
"    </a>",
"    ]. In addition, the risk of suicide in patients with MS may be increased compared with the general population, as shown in most [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/32-35\">",
"     32-35",
"    </a>",
"    ] but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/36\">",
"     36",
"    </a>",
"    ] studies. The median life expectancy in patients with MS is reduced by about 5 to 10 years compared with that of the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/37,38\">",
"     37,38",
"    </a>",
"    ], and suicide probably has only a small effect on the diminished life expectancy in MS. As already noted, depression appears to have a major deleterious impact on cognitive function in patients with MS (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Impact of depression'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    It is not known whether depression in MS patients reflects a comorbid association with bipolar illness or an effect of frontal or subcortical white matter disease. Early trials suggested that treatment with interferon beta may contribute to the development of depression, but subsequent studies have not found such an association [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/39-42\">",
"     39-42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of depression in patients with MS is frequently effective with pharmacotherapy or psychotherapy, although the former may be preferred should depression arise during a course of treatment with a disease modifying agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/43\">",
"     43",
"    </a>",
"    ]. However, data are limited, and a systematic review published in 2011 identified only two small randomized trials of limited quality evaluating the pharmacologic treatment of depression in patients with MS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     FATIGUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fatigue is a characteristic finding in patients with MS, seen in as many as 78 percent of patients. It is usually described as physical exhaustion that is unrelated to the amount of activity performed. Fatigue interferes with daily activities. There appears to be an association between fatigue and disrupted sleep in MS patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Primary MS-related fatigue typically occurs daily and worsens as the day goes on. Many patients also complain of feeling exhausted on waking, even if they have slept soundly. It is often aggravated by heat and humidity. These patients respond best to medications. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Treatment of fatigue'",
"    </a>",
"    below.).",
"   </p>",
"   <p>",
"    Fatigue is often seen in association with an acute attack, and it may precede the focal neurologic features of the attack as well as persist long after the attack has subsided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/46\">",
"     46",
"    </a>",
"    ]. In addition, fatigue has been correlated with measures of cerebral axonal injury, implying a CNS component to the development of fatigue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/47\">",
"     47",
"    </a>",
"    ]. However, there is a poor correlation between fatigue and the overall severity of disease or with the presence of any particular symptom or sign.",
"   </p>",
"   <p>",
"    A number of secondary problems associated with MS can also cause or worsen fatigue. Many of these are treatable and include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sleep disturbances secondary to muscle spasms or bladder problems",
"     </li>",
"     <li>",
"      Depression",
"     </li>",
"     <li>",
"      Mobility limitations",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatable medical causes of fatigue in patients with MS include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anemia",
"     </li>",
"     <li>",
"      Thyroid disorders and chronic thyroid infections",
"     </li>",
"     <li>",
"      Sleep apnea",
"     </li>",
"     <li>",
"      Medications, including antihistamines, antiinflammatory drugs, antihypertensives, heart medications, muscle relaxants, and diabetes therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Treatment of fatigue",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of oral medications may be helpful in treating fatigue related to MS.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"       Amantadine",
"      </a>",
"      (100 mg twice a day) has relatively few side effects and is well tolerated by most patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/48\">",
"       48",
"      </a>",
"      ]. Caution must be taken in patients with renal insufficiency or seizure disorders.",
"     </li>",
"     <li>",
"      Some patients also may respond to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/60/39881?source=see_link\">",
"       methylphenidate",
"      </a>",
"      , 10 to 60 mg per day, in two to three divided doses.",
"     </li>",
"     <li>",
"      Selective serotonin reuptake inhibitors (SSRIs), in addition to treating the depressive symptoms associated with MS, have been used to treat fatigue. We suggest starting with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      10 to 20 mg once or twice daily. A once weekly oral formulation of fluoxetine is also available.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      1300 mg daily was modestly effective compared with placebo for treatment of fatigue in a small, randomized trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/49\">",
"       49",
"      </a>",
"      ]. The benefit of aspirin requires confirmation in larger trials.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/8/1159?source=see_link\">",
"       Modafinil",
"      </a>",
"      is a wakefulness-promoting agent used to treat narcolepsy. Its utility in MS is uncertain. Findings from a preliminary, single-blind study of 72 patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/50\">",
"       50",
"      </a>",
"      ] and a controlled trial with complete data for 19 patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/51\">",
"       51",
"      </a>",
"      ] suggest that modafinil is beneficial for fatigue in MS. However, the largest and most rigorous study, a double-blind placebo-controlled trial of 115 patients with MS, found that modafinil was not effective for fatigue on intention-to-treat analysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/52\">",
"       52",
"      </a>",
"      ]. In addition, modafinil is more expensive than the alternatives listed here. Nevertheless, in the author's clinical experience, modafinil is helpful for MS-related fatigue.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     GAIT IMPAIRMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with MS are affected by gait impairment, and some eventually require a cane or wheelchair. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32458?source=see_link&amp;anchor=H36#H36\">",
"     \"Epidemiology and clinical features of multiple sclerosis in adults\", section on 'Rate of disability progression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Leg weakness and spasticity can result from MS lesions in the descending motor tracts of the brain and spinal cord, and gait imbalance can be caused by lesions involving the cerebellar pathways. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32458?source=see_link&amp;anchor=H18#H18\">",
"     \"Epidemiology and clinical features of multiple sclerosis in adults\", section on 'Motor symptoms'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32458?source=see_link&amp;anchor=H19#H19\">",
"     \"Epidemiology and clinical features of multiple sclerosis in adults\", section on 'Coordination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of gait problems in MS consists mainly of physical therapy along with the use of mobility aids when they become necessary. Measures to treat spasticity may also be helpful. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Spasticity'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Dalfampridine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/36/6725?source=see_link\">",
"     Dalfampridine",
"    </a>",
"    (4-aminopyridine; fampridine), a potassium channel blocker, may improve walking speed in patients with MS. The largest trial randomly assigned 301 ambulatory adults with any type of MS to either sustained-release oral dalfampridine (10 mg twice daily) or to placebo in a 3:1 ratio [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/53\">",
"     53",
"    </a>",
"    ]. The primary outcome was responder status, with responders defined as patients who achieved faster walking speeds in at least three of four visits during the double-blind treatment period than their fastest speed during the off-treatment period.",
"   </p>",
"   <p>",
"    The following observations were noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/53\">",
"     53",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At 14 weeks, the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/36/6725?source=see_link\">",
"       dalfampridine",
"      </a>",
"      group had a significantly higher proportion of patients who met the responder criterion than the placebo group (35 versus 8 percent, odds ratio 4.75, 95% CI 2.08-10.86). In the subset of patients who were responders, the improvement in walking speed was considered clinically meaningful.",
"     </li>",
"     <li>",
"      Two adverse events (anxiety and a focal seizure) were possibly or probably related to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/36/6725?source=see_link\">",
"       dalfampridine",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar results favoring benefit with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/36/6725?source=see_link\">",
"     dalfampridine",
"    </a>",
"    were obtained in an unpublished 14 week randomized controlled trial of analogous design involving 239 ambulatory adults with MS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/54\">",
"     54",
"    </a>",
"    ]. A subsequent randomized controlled trial of dalfampridine reported similar findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/55\">",
"     55",
"    </a>",
"    ]. Based upon the results of the first two trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/53,54\">",
"     53,54",
"    </a>",
"    ], dalfampridine was approved for marketing in the United States to improve walking in patients with MS.",
"   </p>",
"   <p>",
"    Despite approval of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/36/6725?source=see_link\">",
"     dalfampridine",
"    </a>",
"    , it is unclear how the results of these trials apply to clinical practice, since the positive outcomes were determined by a responder analysis rather than by a direct comparison of dalfampridine versus placebo groups for change in walking speed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/56\">",
"     56",
"    </a>",
"    ]. Further research may have an impact on the estimates of benefit and risk, particularly since dalfampridine increases the risk of seizures at higher doses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PAROXYSMAL SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paroxysmal attacks of motor or sensory phenomena can occur with demyelinating lesions. These symptoms are characterized by brief, almost stereotypic, events occurring frequently and often triggered by movement or sensory stimuli. They are likely caused by ephaptic transmission of nerve impulses at sites of previous disease activity. Although troublesome to the patient, these symptoms do not indicate a true exacerbation of MS or cause a loss of myelin in the central nervous system.",
"   </p>",
"   <p>",
"    Within the brainstem, lesions may cause paroxysmal diplopia, facial paresthesia, trigeminal neuralgia, ataxia, and dysarthria. Additional symptoms include, but are not limited to, pain, trunk and limb paresthesia, weakness, ataxia, pruritus, akinesia, and seizures. Motor system involvement may result in dystonia characterized by painful tonic contractions of muscles of one or two (homolateral) limbs, trunk, and occasionally the face; these only rarely occur in all four limbs or the trunk.",
"   </p>",
"   <p>",
"    These paroxysmal attacks typically respond to low doses of anticonvulsants such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    and valproic acid and frequently remit after several weeks to months, usually without recurrence. Newer anticonvulsants such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    also have been used in small case studies. Benzodiazepines are effective in some patients.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/31/36342?source=see_link\">",
"     Baclofen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/40/8840?source=see_link\">",
"     bromocriptine",
"    </a>",
"    are cited as potentially beneficial with these paroxysmal symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SEIZURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epilepsy is more common in patients with MS than in the general population, occurring in 2 to 3 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/57\">",
"     57",
"    </a>",
"    ]. Approximately two-thirds of seizures in patients with MS are primary or secondary generalized seizures, while the remaining one-third are partial. Simple partial seizures are about twice as common as complex partial seizures in patients with MS. This differs from the general population, where complex partial seizures are more frequent than simple partial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Seizures associated with MS are generally are benign and transient and respond well to antiepileptic drug therapy or require no therapy. As an example, in a study of 5715 patients with MS, 51 (0.89 percent) experienced seizure activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/58\">",
"     58",
"    </a>",
"    ]. Generalized tonic-clonic seizures were most common (35 patients, 69 percent), followed by simple or complex partial seizures (11 patients, 22 percent). Of the 45 patients who received antiepileptic drug therapy, 35 (78 percent) became seizure free, while 5 (11 percent) had intractable seizures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SEXUAL DYSFUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexual dysfunction is common in patients with MS. About 50 percent of patients become completely sexually inactive secondary to their disease, and an additional 20 percent become sexually less active [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sexual dysfunction can be the result of multiple problems, including the direct effects of lesions of the motor and sensory pathways within the spinal cord and psychological factors involved with self-image, self-esteem, and fear of rejection from the sexual partner [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/60\">",
"     60",
"    </a>",
"    ]. Mechanical problems created by spasticity, paraparesis, and incontinence further aggravate the problem.",
"   </p>",
"   <p>",
"    Men experience various degrees of erectile dysfunction, often with rapid loss of erection at attempted intercourse; loss of ejaculation is less common. Most women preserve their orgasmic capabilities, sometimes even in the presence of complete loss of bladder and bowel function.",
"   </p>",
"   <p>",
"    Treatment options for sexual dysfunction and impotence have widened with the development of pro-erectile oral medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. The treatment of male and female sexual dysfunction is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/36/30282?source=see_link\">",
"     \"Treatment of male sexual dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/10/34985?source=see_link\">",
"     \"Sexual dysfunction in women: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SPASTICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe spasticity can occur in patients with MS, such that extensor spasms of the legs and sometimes the trunk may be provoked by active or passive attempts to rise from a bed or wheelchair. Spasticity is usually more marked in the legs than in the arms.",
"   </p>",
"   <p>",
"    Oral medications remain the first-line therapy for spasticity in patients with MS. A systematic review of oral agents concluded that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/31/36342?source=see_link\">",
"     baclofen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/35/12855?source=see_link\">",
"     tizanidine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/22/22887?source=see_link\">",
"     dantrolene",
"    </a>",
"    were effective compared with placebo, based on a level of evidence considered fair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/63\">",
"     63",
"    </a>",
"    ]. Baclofen and tizanidine were roughly equivalent in efficacy and had similar rates of adverse events; tizanidine was more often associated with dry mouth, while baclofen was more often associated with motor weakness. There was insufficient evidence to determine the efficacy of dantrolene compared with baclofen or tizanidine.",
"   </p>",
"   <p>",
"    Additional options included intrathecal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/31/36342?source=see_link\">",
"     baclofen",
"    </a>",
"    infusions administered through implantable pumps and botulinum toxin injections. An evidence-based review published in 2008 from the American Academy of Neurology (AAN) concluded that botulinum toxin is effective for reducing muscle tone and improving passive movement in adults with arm and leg spasticity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/64\">",
"     64",
"    </a>",
"    ]. In addition, the AAN concluded that botulinum toxin is probably effective for improving active (ie, voluntary) limb function, although this opinion was based upon results from only one study.",
"   </p>",
"   <p>",
"    Nonpharmacologic interventions for spasticity in MS include physiotherapy, structured exercise programs, transcranial magnetic stimulation, electromagnetic therapy, transcutaneous electrical nerve stimulation, and whole body vibration; none are proven effective, though the available evidence is limited and methodologically weak [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given these data, we suggest",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/31/36342?source=see_link\">",
"     baclofen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/35/12855?source=see_link\">",
"     tizanidine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/22/22887?source=see_link\">",
"     dantrolene",
"    </a>",
"    as initial therapy for spasticity in patients with MS. Among these choices, we prefer baclofen due to its favorable side effect profile and low cost. Daily divided doses of up to 120 mg per day may be used, keeping in mind the possible side effects of drowsiness and hypotonicity. An alternate choice is tizanidine, which may be used alone or in combination with baclofen. Tizanidine tablets are available in 2 mg and 4 mg and may be used in daily divided doses up to 36 mg day.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SPHINCTER DYSFUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bowel and bladder dysfunction are common in patients with MS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/59\">",
"     59",
"    </a>",
"    ]. The extent of sphincter dysfunction often parallels the degree of motor impairment in the lower extremities. The most frequent urinary complaint is urgency, which is usually the result of uninhibited detrusor contraction due to a suprasegmental lesion.",
"   </p>",
"   <p>",
"    Urinary incontinence becomes more common as the disease progresses. With involvement of sacral segments of the spinal cord, symptoms of bladder hypoactivity may evolve, such as decreased urinary flow, interrupted micturition, and incomplete bladder emptying. An atonic dilated bladder that empties by overflow results from loss of perception of bladder fullness, and it is usually associated with urethral, anal, and genital hypesthesia, and sensory deficits in the sacral dermatomes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/48/37642?source=see_link&amp;anchor=H8#H8\">",
"     \"Chronic complications of spinal cord injury\", section on 'Urinary complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subjective complaints of bladder dysfunction in a case series of 297 patients with MS did not correlate with one objective measure (postmicturition residual bladder volume), prompting the authors to recommend ultrasound scanning of residual volume in all patients with MS, even in the absence of subjective urinary symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/66\">",
"     66",
"    </a>",
"    ]. A more restrained approach favored by other experts is to measure postmicturition residual volume in symptomatic patients prior to initiating anticholinergic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other causes of urinary urgency and incontinence also need to be considered in patients with MS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/14/29929?source=see_link\">",
"     \"Clinical presentation and diagnosis of urinary incontinence\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Urinary tract infections are common in MS, particularly in women, and may increase the extent of bladder dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/24/5514?source=see_link\">",
"     \"Recurrent urinary tract infection in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Constipation is more common in MS than fecal incontinence. One study of 221 patients with MS found that 120 (54 percent) had constipation while 64 (29 percent) experienced fecal incontinence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/59\">",
"     59",
"    </a>",
"    ]. These problems may be a result of both upper and lower motor neuron impairment in addition to decreased general mobility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Treatment of sphincter dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of bladder dysfunction in patients with MS involves a combination of suppressing urgency and ensuring effective urinary drainage. Initial therapy for sphincter dysfunction is water restriction and regimented bathroom stops. Anticholinergic drugs remain the primary medical treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/59/10167?source=see_link\">",
"     Oxybutynin",
"    </a>",
"    is a first-line medication for bladder dysfunction. Dosing is 2.5 to 5 mg one to three times per day. There is an extended release preparation as well as a transdermal preparation (oxybutynin 3.9 mg patch twice weekly), which may have the advantage of improved compliance.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/19/14646?source=see_link\">",
"     Tolterodine",
"    </a>",
"    2 mg twice a day is another first-line choice that is also available in a long acting form. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/4/32842?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment of urinary incontinence\", section on 'Antimuscarinics'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/48/37642?source=see_link&amp;anchor=H8#H8\">",
"     \"Chronic complications of spinal cord injury\", section on 'Urinary complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Almost all patients with paraplegia require special measures to maintain regular bowel movements. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/48/37642?source=see_link&amp;anchor=H15#H15\">",
"     \"Chronic complications of spinal cord injury\", section on 'Gastrointestinal complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4942532\">",
"    <span class=\"h1\">",
"     COMPLEMENTARY AND ALTERNATIVE MEDICINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;To manage their symptoms, patients with MS often employ a variety of complementary",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    alternative treatments such as exercise, meditation, yoga, relaxation techniques, acupuncture, cannabis, massage, dietary modification, vitamins, herbs, and mineral supplements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/68-72\">",
"     68-72",
"    </a>",
"    ]. However, there are few high-quality data regarding the utility of these interventions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A course of physiotherapy can improve mobility and enhance mood and subjective well-being in patients with chronic MS, although the effects appear to be short-lived [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Cannabis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Marijuana and cannabinoids have been proposed as symptomatic therapies for MS, and one survey of 220 patients with MS in Nova Scotia found that continuing use of cannabis for symptom treatment was reported by 14 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data regarding the effectiveness of cannabis for MS are limited and have not demonstrated a consistent benefit:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One 15-week randomized trial (the CAMS study) with over 600 patients with MS found no benefit of cannabinoid treatment in an objective measure of spasticity, but patients reported improvements in spasticity and pain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/76\">",
"       76",
"      </a>",
"      ]. These subjective reports may have been biased, however, as many patients were able to accurately identify the active therapy, thus resulting in loss of blinding in the study.",
"     </li>",
"     <li>",
"      A 12-week randomized controlled trial (MUSEC) that enrolled 279 patients with MS reported that the rate of relief from muscle stiffness was significantly greater with cannabis extract compared with placebo (29 versus 16 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/77\">",
"       77",
"      </a>",
"      ]. There was no assessment regarding whether subjects were able to accurately identify active therapy.",
"     </li>",
"     <li>",
"      In small, randomized, blinded trials, a modest improvement in central neuropathic pain was observed after treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/49/30485?source=see_link\">",
"       dronabinol",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/78\">",
"       78",
"      </a>",
"      ] and after treatment with an oromucosal spray formulation of cannabis compounds [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A randomized, crossover trial evaluating tremor in 14 patients with MS found that oral cannador (cannabis extract) was associated with no significant improvement in any of the objective measures of upper limb tremor compared with placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/7/36985/abstract/80\">",
"       80",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/31/40447?source=see_link\">",
"       \"Patient information: Multiple sclerosis in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1126331\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Frank dementia is an uncommon feature of multiple sclerosis (MS) and is usually only encountered in severely affected individuals. However, 43 to 70 percent of patients have cognitive impairment on the basis of neuropsychological testing. Depression frequently has a negative impact on cognition, particularly on memory, attention, and concentration. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Cognitive dysfunction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Impact of depression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no proven therapies for cognitive dysfunction in MS. Nonpharmacologic approaches consist primarily of support and improvement of coping strategies. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Disease modifying therapies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Cholinesterase inhibitors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Nonpharmacologic approaches'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is some degree of affective disturbance in up to two-thirds of patients with MS. Depression is the most common manifestation; it occurs in part due to the burden of having to cope with a chronic, incurable disease. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Depression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fatigue is a characteristic finding in patients with MS. It is usually described as physical exhaustion that is unrelated to the amount of activity performed. A number of medications may be helpful in treating fatigue related to MS, including",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"       amantadine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/60/39881?source=see_link\">",
"       methylphenidate",
"      </a>",
"      , and others. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Fatigue'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of gait problems in MS and consists mainly of physical therapy along with the use of mobility aids when they become necessary. Measures to treat spasticity may also be helpful.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/36/6725?source=see_link\">",
"       Dalfampridine",
"      </a>",
"      may improve walking speed in patients with MS. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Gait impairment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Dalfampridine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Paroxysmal attacks of motor or sensory phenomena can occur with demyelinating lesions. These symptoms are characterized by brief, almost stereotypic, events occurring frequently and often triggered by movement or sensory stimuli. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Paroxysmal symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Epilepsy occurs in 2 to 3 percent of patients with MS. Seizures associated with MS are generally benign and transient and respond well to antiepileptic drug therapy or require no therapy. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Seizures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      About 50 percent of patients with MS become completely sexually inactive secondary to their disease, and an additional 20 percent become sexually less active. Treatment options for sexual dysfunction and impotence have widened with the development of pro-erectile oral medications. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Sexual dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Severe spasticity can occur in patients with MS, and is usually more marked in the legs than in the arms. For patients with MS who have clinically significant spasticity, we suggest initial treatment with oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/31/36342?source=see_link\">",
"       baclofen",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/35/12855?source=see_link\">",
"       tizanidine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/22/22887?source=see_link\">",
"       dantrolene",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Among these choices, we prefer oral baclofen due to its favorable side effect profile and low cost. Additional options included intrathecal baclofen infusions and botulinum toxin injections. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Spasticity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bowel and bladder dysfunction are common in patients with MS. The most frequent urinary complaint is urgency, which is usually the result of uninhibited detrusor contraction due to a suprasegmental lesion. Urinary incontinence becomes more common as the disease progresses. Treatment of bladder dysfunction involves a combination of suppressing urgency and ensuring effective urinary drainage. Initial therapy for sphincter dysfunction is water restriction and regimented bathroom stops. Anticholinergic drugs remain the primary medical treatment. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Sphincter dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To manage their symptoms, patients with MS often employ a variety of complementary",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      alternative treatments such as exercise, meditation, yoga, relaxation techniques, acupuncture, cannabis, massage, dietary modification, vitamins, herbs, and mineral supplements. However, there are few high-quality data regarding the utility of these interventions. (See",
"      <a class=\"local\" href=\"#H4942532\">",
"       'Complementary and alternative medicine'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/1\">",
"      Staff NP, Lucchinetti CF, Keegan BM. Multiple sclerosis with predominant, severe cognitive impairment. Arch Neurol 2009; 66:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/2\">",
"      Chiaravalloti ND, DeLuca J. Cognitive impairment in multiple sclerosis. Lancet Neurol 2008; 7:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/3\">",
"      Achiron A, Barak Y. Cognitive impairment in probable multiple sclerosis. J Neurol Neurosurg Psychiatry 2003; 74:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/4\">",
"      Deloire MS, Salort E, Bonnet M, et al. Cognitive impairment as marker of diffuse brain abnormalities in early relapsing remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2005; 76:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/5\">",
"      Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 1991; 41:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/6\">",
"      Huijbregts SC, Kalkers NF, de Sonneville LM, et al. Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS. Neurology 2004; 63:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/7\">",
"      Franklin GM, Heaton RK, Nelson LM, et al. Correlation of neuropsychological and MRI findings in chronic/progressive multiple sclerosis. Neurology 1988; 38:1826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/8\">",
"      Hohol MJ, Guttmann CR, Orav J, et al. Serial neuropsychological assessment and magnetic resonance imaging analysis in multiple sclerosis. Arch Neurol 1997; 54:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/9\">",
"      Rao SM, Leo GJ, Haughton VM, et al. Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis. Neurology 1989; 39:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/10\">",
"      Calabrese M, Agosta F, Rinaldi F, et al. Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. Arch Neurol 2009; 66:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/11\">",
"      Amato MP, Bartolozzi ML, Zipoli V, et al. Neocortical volume decrease in relapsing-remitting MS patients with mild cognitive impairment. Neurology 2004; 63:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/12\">",
"      Sanfilipo MP, Benedict RH, Weinstock-Guttman B, Bakshi R. Gray and white matter brain atrophy and neuropsychological impairment in multiple sclerosis. Neurology 2006; 66:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/13\">",
"      Calabrese M, Rinaldi F, Mattisi I, et al. Widespread cortical thinning characterizes patients with MS with mild cognitive impairment. Neurology 2010; 74:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/14\">",
"      Filippi M, Rocca MA, Benedict RH, et al. The contribution of MRI in assessing cognitive impairment in multiple sclerosis. Neurology 2010; 75:2121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/15\">",
"      Mesaros S, Rocca MA, Kacar K, et al. Diffusion tensor MRI tractography and cognitive impairment in multiple sclerosis. Neurology 2012; 78:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/16\">",
"      Zagzag D, Miller DC, Kleinman GM, et al. Demyelinating disease versus tumor in surgical neuropathology. Clues to a correct pathological diagnosis. Am J Surg Pathol 1993; 17:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/17\">",
"      Gilchrist AC, Creed FH. Depression, cognitive impairment and social stress in multiple sclerosis. J Psychosom Res 1994; 38:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/18\">",
"      Mohr DC, Goodkin DE, Gatto N, Van der Wende J. Depression, coping and level of neurological impairment in multiple sclerosis. Mult Scler 1997; 3:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/19\">",
"      Arnett PA, Higginson CI, Randolph JJ. Depression in multiple sclerosis: relationship to planning ability. J Int Neuropsychol Soc 2001; 7:665.",
"     </a>",
"    </li>",
"    <li>",
"     Baddeley, AD, Hitch, GJ. Working Memory. In: The Psychology of Learning and Motivation, Bower, GH (Ed), Academic Press, San Diego 1974. p.47.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/21\">",
"      Arnett PA, Higginson CI, Voss WD, et al. Depressed mood in multiple sclerosis: relationship to capacity-demanding memory and attentional functioning. Neuropsychology 1999; 13:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/22\">",
"      Thornton AE, Raz N. Memory impairment in multiple sclerosis: a quantitative review. Neuropsychology 1997; 11:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/23\">",
"      Arnett PA, Higginson CI, Voss WD, et al. Depression in multiple sclerosis: relationship to working memory capacity. Neuropsychology 1999; 13:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/24\">",
"      Patti F. Treatment of cognitive impairment in patients with multiple sclerosis. Expert Opin Investig Drugs 2012; 21:1679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/25\">",
"      Krupp LB, Christodoulou C, Melville P, et al. Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology 2004; 63:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/26\">",
"      Shaygannejad V, Janghorbani M, Ashtari F, et al. Effects of rivastigmine on memory and cognition in multiple sclerosis. Can J Neurol Sci 2008; 35:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/27\">",
"      Krupp LB, Christodoulou C, Melville P, et al. Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis. Neurology 2011; 76:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/28\">",
"      Pepping M, Ehde DM. Neuropsychological evaluation and treatment of multiple sclerosis: the importance of a neuro-rehabilitation focus. Phys Med Rehabil Clin N Am 2005; 16:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/29\">",
"      Rosti-Otaj&auml;rvi EM, H&auml;m&auml;l&auml;inen PI. Neuropsychological rehabilitation for multiple sclerosis. Cochrane Database Syst Rev 2011; :CD009131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/30\">",
"      Rao SM, Reingold SC, Ron MA, et al. Workshop on Neurobehavioral Disorders in Multiple Sclerosis. Diagnosis, underlying disease, natural history, and therapeutic intervention, Bergamo, Italy, June 25-27, 1992. Arch Neurol 1993; 50:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/31\">",
"      Patten SB, Beck CA, Williams JV, et al. Major depression in multiple sclerosis: a population-based perspective. Neurology 2003; 61:1524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/32\">",
"      Sadovnick AD, Eisen K, Ebers GC, Paty DW. Cause of death in patients attending multiple sclerosis clinics. Neurology 1991; 41:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/33\">",
"      Stenager EN, Stenager E. Suicide and patients with neurologic diseases. Methodologic problems. Arch Neurol 1992; 49:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/34\">",
"      Fredrikson S, Cheng Q, Jiang GX, Wasserman D. Elevated suicide risk among patients with multiple sclerosis in Sweden. Neuroepidemiology 2003; 22:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/35\">",
"      Br&oslash;nnum-Hansen H, Stenager E, Nylev Stenager E, Koch-Henriksen N. Suicide among Danes with multiple sclerosis. J Neurol Neurosurg Psychiatry 2005; 76:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/36\">",
"      Sumelahti ML, Tienari PJ, Wikstr&ouml;m J, et al. Survival of multiple sclerosis in Finland between 1964 and 1993. Mult Scler 2002; 8:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/37\">",
"      Br&oslash;nnum-Hansen H, Koch-Henriksen N, Stenager E. Trends in survival and cause of death in Danish patients with multiple sclerosis. Brain 2004; 127:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/38\">",
"      Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/39\">",
"      Patten SB, Metz LM, SPECTRIMS Study Group. Interferon beta1a and depression in secondary progressive MS: data from the SPECTRIMS Trial. Neurology 2002; 59:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/40\">",
"      Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet 1998; 352:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/41\">",
"      Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/42\">",
"      Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998; 352:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/43\">",
"      Feinstein A. Multiple sclerosis, disease modifying treatments and depression: a critical methodological review. Mult Scler 2000; 6:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/44\">",
"      Koch MW, Glazenborg A, Uyttenboogaart M, et al. Pharmacologic treatment of depression in multiple sclerosis. Cochrane Database Syst Rev 2011; :CD007295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/45\">",
"      Attarian HP, Brown KM, Duntley SP, et al. The relationship of sleep disturbances and fatigue in multiple sclerosis. Arch Neurol 2004; 61:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/46\">",
"      Bakshi R, Miletich RS, Henschel K, et al. Fatigue in multiple sclerosis: cross-sectional correlation with brain MRI findings in 71 patients. Neurology 1999; 53:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/47\">",
"      Tartaglia MC, Narayanan S, Francis SJ, et al. The relationship between diffuse axonal damage and fatigue in multiple sclerosis. Arch Neurol 2004; 61:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/48\">",
"      Taus C, Giuliani G, Pucci E, et al. Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev 2003; :CD002818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/49\">",
"      Wingerchuk DM, Benarroch EE, O'Brien PC, et al. A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis. Neurology 2005; 64:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/50\">",
"      Rammohan KW, Rosenberg JH, Lynn DJ, et al. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psychiatry 2002; 72:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/51\">",
"      Lange R, Volkmer M, Heesen C, Liepert J. Modafinil effects in multiple sclerosis patients with fatigue. J Neurol 2009; 256:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/52\">",
"      Stankoff B, Waubant E, Confavreux C, et al. Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology 2005; 64:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/53\">",
"      Goodman AD, Brown TR, Krupp LB, et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 2009; 373:732.",
"     </a>",
"    </li>",
"    <li>",
"     Safety and efficacy study of oral fampridine-SR on walking ability in multiple sclerosis file://clinicaltrials.gov/ct2/show/NCT00053417?term=NCT00053417&amp;rank=1 (Accessed on March 09, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/55\">",
"      Goodman AD, Brown TR, Edwards KR, et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 2010; 68:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/56\">",
"      Thompson A, Polman C. Improving function: a new treatment era for multiple sclerosis? Lancet 2009; 373:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/57\">",
"      Koch M, Uyttenboogaart M, Polman S, De Keyser J. Seizures in multiple sclerosis. Epilepsia 2008; 49:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/58\">",
"      Nyquist PA, Cascino GD, Rodriguez M. Seizures in patients with multiple sclerosis seen at Mayo Clinic, Rochester, Minn, 1990-1998. Mayo Clin Proc 2001; 76:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/59\">",
"      Hennessey A, Robertson NP, Swingler R, Compston DA. Urinary, faecal and sexual dysfunction in patients with multiple sclerosis. J Neurol 1999; 246:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/60\">",
"      Zivadinov R, Zorzon M, Bosco A, et al. Sexual dysfunction in multiple sclerosis: II. Correlation analysis. Mult Scler 1999; 5:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/61\">",
"      DasGupta R, Fowler CJ. Sexual and urological dysfunction in multiple sclerosis: better understanding and improved therapies. Curr Opin Neurol 2002; 15:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/62\">",
"      Fowler CJ, Miller JR, Sharief MK, et al. A double blind, randomised study of sildenafil citrate for erectile dysfunction in men with multiple sclerosis. J Neurol Neurosurg Psychiatry 2005; 76:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/63\">",
"      Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage 2004; 28:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/64\">",
"      Simpson DM, Gracies JM, Graham HK, et al. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 70:1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/65\">",
"      Amatya B, Khan F, La Mantia L, et al. Non pharmacological interventions for spasticity in multiple sclerosis. Cochrane Database Syst Rev 2013; 2:CD009974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/66\">",
"      Kragt JJ, Hoogervorst EL, Uitdehaag BM, Polman CH. Relation between objective and subjective measures of bladder dysfunction in multiple sclerosis. Neurology 2004; 63:1716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/67\">",
"      Fowler CJ, Panicker JN, Drake M, et al. A UK consensus on the management of the bladder in multiple sclerosis. J Neurol Neurosurg Psychiatry 2009; 80:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/68\">",
"      Olsen SA. A review of complementary and alternative medicine (CAM) by people with multiple sclerosis. Occup Ther Int 2009; 16:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/69\">",
"      Yadav V, Bourdette D. Complementary and alternative medicine: is there a role in multiple sclerosis? Curr Neurol Neurosci Rep 2006; 6:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/70\">",
"      Oken BS, Kishiyama S, Zajdel D, et al. Randomized controlled trial of yoga and exercise in multiple sclerosis. Neurology 2004; 62:2058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/71\">",
"      Apel A, Greim B, K&ouml;nig N, Zettl UK. Frequency of current utilisation of complementary and alternative medicine by patients with multiple sclerosis. J Neurol 2006; 253:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/72\">",
"      Grossman P, Kappos L, Gensicke H, et al. MS quality of life, depression, and fatigue improve after mindfulness training: a randomized trial. Neurology 2010; 75:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/73\">",
"      Tavee J, Stone L. Healing the mind: meditation and multiple sclerosis. Neurology 2010; 75:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/74\">",
"      Wiles CM, Newcombe RG, Fuller KJ, et al. Controlled randomised crossover trial of the effects of physiotherapy on mobility in chronic multiple sclerosis. J Neurol Neurosurg Psychiatry 2001; 70:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/75\">",
"      Clark AJ, Ware MA, Yazer E, et al. Patterns of cannabis use among patients with multiple sclerosis. Neurology 2004; 62:2098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/76\">",
"      Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003; 362:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/77\">",
"      Zajicek JP, Hobart JC, Slade A, et al. Multiple sclerosis and extract of cannabis: results of the MUSEC trial. J Neurol Neurosurg Psychiatry 2012; 83:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/78\">",
"      Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004; 329:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/79\">",
"      Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005; 65:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36985/abstract/80\">",
"      Fox P, Bain PG, Glickman S, et al. The effect of cannabis on tremor in patients with multiple sclerosis. Neurology 2004; 62:1105.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1690 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-60.18.131.125-8B92F8E3C2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_7_36985=[""].join("\n");
var outline_f36_7_36985=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1126331\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      COGNITIVE DYSFUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Impact of depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pharmacologic treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Disease modifying therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Cholinesterase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Nonpharmacologic approaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DEPRESSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      FATIGUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Treatment of fatigue",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      GAIT IMPAIRMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Dalfampridine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PAROXYSMAL SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SEIZURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SEXUAL DYSFUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SPASTICITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SPHINCTER DYSFUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Treatment of sphincter dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4942532\">",
"      COMPLEMENTARY AND ALTERNATIVE MEDICINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Cannabis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1126331\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/48/37642?source=related_link\">",
"      Chronic complications of spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/14/29929?source=related_link\">",
"      Clinical presentation and diagnosis of urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35130?source=related_link\">",
"      Diagnosis of multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32458?source=related_link\">",
"      Epidemiology and clinical features of multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/31/40447?source=related_link\">",
"      Patient information: Multiple sclerosis in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/24/5514?source=related_link\">",
"      Recurrent urinary tract infection in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/10/34985?source=related_link\">",
"      Sexual dysfunction in women: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/36/30282?source=related_link\">",
"      Treatment of male sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/41/26265?source=related_link\">",
"      Treatment of progressive multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/7/41082?source=related_link\">",
"      Treatment of relapsing-remitting multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/4/32842?source=related_link\">",
"      Treatment of urinary incontinence",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_7_36986="Cutaneous complications of conventional chemotherapy agents";
var content_f36_7_36986=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"9\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cutaneous complications of conventional chemotherapy agents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/7/36986/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/7/36986/contributors\">",
"     Aimee S Payne, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/7/36986/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/7/36986/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/7/36986/contributors\">",
"     Reed E Drews, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/7/36986/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/7/36986/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/7/36986/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 23, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic and local treatments for cancer can cause a number of changes in the skin, mucous membranes, hair, and nails [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. When dermatologic lesions arise in patients being treated for cancer, they may represent a side effect of therapy, but other etiologies need to be considered. These include a cutaneous reaction to other drugs, exacerbation of a previously existing condition, infection, metastatic tumor involvement, a paraneoplastic phenomenon, graft-versus-host disease, or a nutritional disorder.",
"   </p>",
"   <p>",
"    Accurate diagnosis and management of chemotherapy-related side effects require the clinician to be knowledgeable of the most commonly reported cutaneous reaction patterns for the drugs the patient is receiving. The clinician must also be familiar with the cutaneous manifestations of certain cancers, as well as the dermatologic effects of other forms of cancer treatments. In some cases, diagnostic uncertainty can only be clarified with a rechallenge, and the clinician must determine whether rechallenge is medically justifiable.",
"   </p>",
"   <p>",
"    The cutaneous complications of conventional cytotoxic cancer therapy agents are presented here. Related topics discussed elsewhere include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35834?source=see_link\">",
"       \"Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cutaneous manifestations of malignancy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/18/21802?source=see_link\">",
"       \"Cutaneous manifestations of internal malignancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Extravasation injury. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/13/218?source=see_link\">",
"       \"Extravasation injury from chemotherapy and other non-neoplastic vesicants\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chemotherapy-induced alopecia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/12/44232?source=see_link\">",
"       \"Chemotherapy-induced alopecia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Graft-versus-host disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/25/23962?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and grading of chronic graft-versus-host disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/22/25960?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Stomatitis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/22/38250?source=see_link\">",
"       \"Oral toxicity associated with chemotherapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Systemic hypersensitivity reactions. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/57/43930?source=see_link\">",
"       \"Infusion reactions to systemic chemotherapy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IMMUNE-MEDIATED HYPERSENSITIVITY REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virtually all chemotherapeutic agents have the potential to initiate an infusion reaction, although few are immune-mediated. Various types of skin rashes can accompany infusion reactions with a variety of chemotherapy drugs, both in the setting of an anaphylactic reaction or a mild \"standard infusion reaction\". Infusion reactions to specific chemotherapy agents and issues related to prophylaxis and management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/57/43930?source=see_link\">",
"     \"Infusion reactions to systemic chemotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following is a brief synopsis of the types of immune-mediated hypersensitivity reactions that can either directly or indirectly affect the skin and mucous membranes, and their clinical manifestations.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most infusion reactions with the platinum drugs (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      ) are classic type I IgE-mediated allergic reactions (",
"      <a class=\"graphic graphic_table graphicRef71375 \" href=\"mobipreview.htm?13/23/13692\">",
"       table 1",
"      </a>",
"      ). Urticaria, pruritus, angioedema, and other symptoms of anaphylaxis typically develop within one hour of drug administration, although such reactions may occur up to 24 hours following exposure.",
"     </li>",
"     <li>",
"      Type III reactions result from formation and tissue deposition of antigen-antibody complexes. Type III reactions may be responsible for drug-induced erythema multiforme, the cutaneous vasculitis seen with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/5,6\">",
"       5,6",
"      </a>",
"      ], and the serum-sickness-like reaction following infusion of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/40/8842?source=see_link\">",
"       \"Serum sickness and serum sickness-like reactions\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Type IV reactions are mediated by activated T cells. Contact dermatitis to topical",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/57/40853?source=see_link\">",
"       mechlorethamine",
"      </a>",
"      (nitrogen mustard) is an example of a classic type IV allergic reaction to a chemotherapy agent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/7-9\">",
"       7-9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/35/36410?source=see_link\">",
"       \"Treatment of advanced stage (IIB to IV) mycosis fungoides and S&eacute;zary syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other immune-mediated mechanisms that are not well understood are thought to underlie toxic epidermal necrolysis and certain allergic exanthematous drug rashes. (See",
"    <a class=\"local\" href=\"#H33\">",
"     'Erythema multiforme, SJS, and toxic epidermal necrolysis'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H32\">",
"     'Diffuse erythema and exfoliative dermatitis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PIGMENTARY CHANGES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pigmentary changes involving the skin, nails, and mucous membranes are common in patients receiving cytotoxic drugs, particularly alkylating agents and antitumor antibiotics (",
"    <a class=\"graphic graphic_table graphicRef60304 \" href=\"mobipreview.htm?33/43/34492\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/10\">",
"     10",
"    </a>",
"    ]. The area of enhanced pigmentation may be localized or more diffuse, and it may affect the skin, mucous membranes, hair,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nails. The pigmentary changes usually resolve with drug discontinuation, but may persist. As an example, the rare gingival margin hyperpigmentation seen with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    is usually permanent.",
"   </p>",
"   <p>",
"    Pigmentary changes may be diffuse or localized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Fluoropyrimidines",
"    </span>",
"    &nbsp;&mdash;&nbsp;5-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    (5-FU) is one of the most ubiquitous drugs used in the treatment of cancer patients. It is often associated with a hyperpigmentation reaction that may affect the skin diffusely or locally (in sun-exposed areas), in a serpentine manner (a pigmentary pattern that follows an underlying vein proximal to an infusion site), darken the nail beds, and induce mucosal pigmentation of the tongue and conjunctiva. Topical 5-fluorouracil (5-FU) can induce hyperpigmentation in treated areas. The 5-FU derivative tegafur can induce well-circumscribed, brown to black macular pigmentation that appears on the palms, soles, nails and glans penis; the localization in these cases is unexplained. Hyperpigmentation associated with 5-fluorouracil usually resolves within weeks to several months after cessation of therapy; however, in certain cases nail hyperpigmentation may persist for years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/11-15\">",
"     11-15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Other drugs",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Diffuse reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to 5-FU, many systemic medications induce pigmentary reaction patterns that affect the skin in a diffuse manner. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"       Busulfan",
"      </a>",
"      causes a generalized skin darkening (the so-called \"busulfan tan\") that can mimic the cutaneous manifestations of Addison's disease. Although busulfan can also cause adrenal insufficiency, the skin pigmentary change is thought instead to be secondary to a toxic effect on melanocytes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. Features that can help to distinguish cutaneous busulfan toxicity from true Addison's disease include normal levels of melanocyte-stimulating hormone and adrenocorticotropic hormone (ACTH). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/0/33800?source=see_link\">",
"       \"Clinical manifestations of adrenal insufficiency in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/13/10458?source=see_link\">",
"       Pegylated liposomal doxorubicin",
"      </a>",
"      can induce a macular hyperpigmentation over the trunk and extremities, including the palms and soles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/18\">",
"       18",
"      </a>",
"      ]. This reaction has not been described with unencapsulated",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Hyperpigmentation due to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      may affect the face, neck, lower arms, palms, and nails; pigmentation can also be accentuated in areas of pressure or trauma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]. This pressure phenomenon is also reported for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      can rarely induce a diffuse brown skin hyperpigmentation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"       Procarbazine",
"      </a>",
"      has been associated with generalized melanosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Local",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local changes in skin pigmentation may be associated with intrinsic, anatomic features of the skin (eg, mucous membranes, skin creases, flexural or intertriginous areas, palms or soles, and face). However, a suspected local drug reaction may be due to other extrinsic factors which act in combination with the drug. In addition to 5-FU, other examples include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35414?source=see_link\">",
"     thiotepa",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    (sites of adhesive placement on the skin);",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    (sites of trauma or pressure); and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    (sun-exposed areas) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/1,24\">",
"     1,24",
"    </a>",
"    ]. The local hyperpigmentation seen in areas of skin exposed to adhesive may reflect secretion of the drug in sweat.",
"   </p>",
"   <p>",
"    Some of these reactions may represent postinflammatory hyperpigmentation rather than a local effect of the drug itself, especially if administration of the agent is associated with trauma, skin irritation, or a local allergic reaction (ie, contact dermatitis).",
"   </p>",
"   <p>",
"    The following are examples of local chemotherapy-induced hyperpigmentation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pigmentary changes caused by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"       busulfan",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      have a predilection for flexural areas and palmar creases.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       Ifosfamide",
"      </a>",
"      hyperpigmentation can occur in flexural areas, dorsal and plantar surfaces of the feet, extensor surfaces of fingers and toes, on the scrotum, and occasionally on large areas of the trunk; it may also occur under occlusive dressings.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/31/37368?source=see_link\">",
"       Mitoxantrone",
"      </a>",
"      hyperpigmentation can affect the face, dorsum of the hands, and nails.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/15/43254?source=see_link\">",
"       Daunorubicin",
"      </a>",
"      may induce annular or polycyclic pigmentation of the scalp [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mucosal hyperpigmentation has been associated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"       busulfan",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (gingiva), tegafur (lower lip as well as glans penis, see above),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      (tongue and buccal mucosa), and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/1\">",
"       1",
"      </a>",
"      ] as well as 5-FU.",
"     </li>",
"     <li>",
"      Like topical 5-FU, topical",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/57/40853?source=see_link\">",
"       mechlorethamine",
"      </a>",
"      can induce hyperpigmentation in treated areas.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Serpentine and flagellate hyperpigmentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serpentine hyperpigmentation describes a supravenous pigmentary pattern that follows an underlying vein proximal to an infusion site. This phenomenon is most commonly seen with 5-FU, but has also been associated with fotemustine,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"     vinorelbine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serpentine hyperpigmentation has also been reported with some combination regimens, such as CHOP (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) for lymphoma treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Linear streaking (flagellate hyperpigmentation) may be seen with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Hair",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to causing alopecia, chemotherapy can also cause pigmentary changes in hair. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/12/44232?source=see_link\">",
"     \"Chemotherapy-induced alopecia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Both",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      can induce hair color change; with cyclophosphamide the range is from light red to black.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      may induce hyperpigmentation of scalp hair, eyebrow hair, and eyelashes; this tends to occur in bands that alternate with the normal color, a feature known as the \"flag sign\" [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/29\">",
"       29",
"      </a>",
"      ]. This results from alternating periods of treatment and no treatment.",
"     </li>",
"     <li>",
"      One man receiving therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      experienced hair color change from black to red [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     NAIL DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonspecific nail changes are commonly observed in patients with severe illness. As an example, deep transverse depressions (Beau's lines) in the nail plate of both the fingernails and toenails are due to prolonged inactivation of nail matrix activity (",
"    <a class=\"graphic graphic_picture graphicRef62607 graphicRef78502 \" href=\"mobipreview.htm?1/46/1766\">",
"     picture 1A-B",
"    </a>",
"    ). This process can lead to a complete separation of the two ends of the nail plate (onychomadesis). Fingernails grow approximately 0.1 mm per day; thus the distance of a Beau's line from the proximal nail fold gives an approximate indication of when the acute insult occurred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, a few chemotherapeutic agents have been associated with specific dystrophic nail reaction patterns, including pigmentary changes and onycholysis, a detachment of the overlying nail from the nail bed. Other inflammatory reaction patterns involving the nail include pyogenic granuloma and acute exudative paronychia that may progress to subungual abscess.",
"   </p>",
"   <p>",
"    The various nail disorders that are associated with individual chemotherapy agents are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef72242 \" href=\"mobipreview.htm?33/22/34156\">",
"     table 3",
"    </a>",
"    ), and some are described below. After discontinuation of chemotherapy, all of these conditions generally resolve as the nail grows out.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pigmentary changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications may induce diffuse hyperpigmentation or",
"    <span class=\"nowrap\">",
"     banding/streaking",
"    </span>",
"    of the nail plate or bed. Besides 5-FU, a wide range of agents have been implicated, including alkylating agents, taxanes, antimetabolites (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ), anthracyclines, antitumor antibiotics, among others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Onycholysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Onycholysis is caused by inflammation in the nail bed, which leads to detachment of the overlying nail. The cytotoxic drugs most frequently associated with onycholysis are the taxanes",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    (",
"    <a class=\"graphic graphic_picture graphicRef63373 \" href=\"mobipreview.htm?10/46/10991\">",
"     picture 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/4\">",
"     4",
"    </a>",
"    ]. Other medications that have been reported to cause onycholysis include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10423?source=see_link\">",
"     ixabepilone",
"    </a>",
"    , and the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/1,31\">",
"     1,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An intriguing association between denervation and protection from chemotherapy-induced nail changes was suggested in a report of a patient with a complete right arm nerve palsy due to advanced breast cancer who developed",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    -related nail changes in all extremities except the paretic hand [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At least two small controlled studies (in which one side of the body was treated and the other untreated as the control) suggest that cold therapy (ie, application of a frozen sock, glove) for 90 minutes (15 minutes before, during, and 15 minutes after drug infusion) significantly reduces the incidence of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    nail (and skin) toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. The incidence of grade 1 to 2 nail toxicity was 11 versus 52 percent in the frozen glove and control groups, respectively, in one of the studies, and only 11 percent of patients experienced discomfort because of cold intolerance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Severe nail toxicity occurs only in a minority of patients and is primarily a cosmetic concern. Furthermore, cold therapy may reduce exposure of the extremity to the therapeutic agent, which in theory may permit persistence of metastatic tumor cells in that location. Thus, the use of cold therapy must be decided on a case by case basis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Inflammatory changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of infectious and noninfectious inflammatory changes around and under the nail have been reported.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Painful paronychial inflammation, often associated with pyogenic granulomas, may be induced by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      . This is also seen with the epidermal growth factor inhibitors",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"       gefitinib",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35834?source=see_link\">",
"       \"Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      may induce an exudative paronychia with or without progression to frank abscess [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PHOTOSENSITIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increased sensitivity to ultraviolet (UV) light exposure (photosensitivity) has been associated with a variety of chemotherapy agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/1,35-37\">",
"     1,35-37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/17/41241?source=see_link&amp;anchor=H12#H12\">",
"     \"Drug eruptions\", section on 'Photosensitivity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Photosensitivity reactions can be manifested in a variety of ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A phototoxic reaction, which is characterized by the onset of severe erythema within minutes to hours following light exposure. These reactions are not immunologically mediated, and they usually spare sun-protected areas.",
"     </li>",
"     <li>",
"      A photoallergic reaction, which is a type IV hypersensitivity reaction (",
"      <a class=\"graphic graphic_table graphicRef71375 \" href=\"mobipreview.htm?13/23/13692\">",
"       table 1",
"      </a>",
"      ) that develops at least 24 hours after light exposure. Photoallergic reactions may spread to involve nonsun-exposed areas and usually cause dermatitis rather than erythema.",
"     </li>",
"     <li>",
"      Photoreactivation, in which the administration of a chemotherapy drug (typically",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ) in the absence of light can trigger a sunburn-like reaction in the same distribution as a sunburn that the patient may have sustained months to years before.",
"     </li>",
"     <li>",
"      In contrast, a photoenhancement reaction can occur when patients who receive a drug (typically high-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ) within two to five days of exposure to UV light develop severe erythema within the sun-exposed areas.",
"     </li>",
"     <li>",
"      Photoonycholysis, in which a drug-mediated reaction to light leads to separation of the nail bed from the nail plate, most commonly affecting the distal nail.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Phototoxic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A phototoxic reaction resembles an exaggerated sunburn, with erythema, edema, pain, and tenderness in sun-exposed areas such as the face, the \"V\" area of the upper chest, and the dorsa of the hands. In severe cases, blistering can occur. Postinflammatory hyperpigmentation is common.",
"   </p>",
"   <p>",
"    The clinical diagnosis is based upon the distribution of the eruption (ie, a sharp demarcation between sun exposed versus protected sites) and the temporal relationship to administration of the offending agent. If the diagnosis is in doubt, photo patch testing can be used as adjunctive diagnostic measures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of phototoxic chemotherapy reactions is thought to involve concentration of the drug within the skin and subsequent absorption of UV light, resulting in apoptosis of keratinocytes. On biopsy, the characteristic histologic findings include dyskeratotic keratinocytes, a vacuolar interface dermatitis, and papillary dermal edema with minimal inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of phototoxic reactions involves discontinuation of the offending agent and avoidance of direct exposure to sunlight through the use of protective clothing and a topical sunscreen for at least two weeks. Physical sunscreens containing titanium oxide or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/53/15187?source=see_link\">",
"     zinc oxide",
"    </a>",
"    are preferred because chemical sunscreens, especially oxybenzone, can be associated with photoallergic reactions. Symptomatic treatment with cool compresses and topical steroids may be helpful. Severe cases may require systemic steroids.",
"   </p>",
"   <p>",
"    Patients receiving photosensitizing drugs should be counseled regarding the risk of adverse reactions to sunlight and encouraged to use UV protection with sunscreens and protective clothing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Photoallergic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to phototoxic reactions, a photoallergic reaction is characterized by pruritus rather than burning, with a papulovesicular eruption, erythema,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    scaling over sun-exposed areas. Photosensitivity reactions to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/23/4470?source=see_link\">",
"     flutamide",
"    </a>",
"    and tegafur are typically photoallergic rather than phototoxic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/35,39,40\">",
"     35,39,40",
"    </a>",
"    ]. Symptoms generally clear within four to eight weeks after drug discontinuation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Photoreactivation and photoenhancement",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    can cause a phototoxic recall reaction (photoreactivation) in which drug administration in the absence of light triggers a sunburn-like reaction in the same distribution as a sunburn that the patient may have sustained months or years earlier [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Symptoms are usually reproduced with rechallenge.",
"   </p>",
"   <p>",
"    High-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    is also associated with photoenhancement reactions, in which drug administration within two to five days after exposure to UV light causes severe erythema in sun-exposed areas.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     Leucovorin",
"    </a>",
"    rescue is ineffective at preventing these reactions. In contrast to photoreactivation, retreatment with methotrexate usually does not reproduce this reaction.",
"   </p>",
"   <p>",
"    There are isolated reports of a similar photoenhancement phenomenon with taxanes,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/13/10458?source=see_link\">",
"     pegylated liposomal doxorubicin",
"    </a>",
"    , and some cytotoxic combination regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/43-47\">",
"     43-47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Photoonycholysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Photoonycholysis is a unique adverse light reaction caused by the combination of certain chemotherapeutic agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/43/37559?source=see_link\">",
"     mercaptopurine",
"    </a>",
"    ) with UV light [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Separation of the nail bed from the nail plate most commonly affects the distal nail and occurs two to four weeks after drug administration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS AND SCLERODERMA-LIKE CHANGES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subacute cutaneous lupus erythematosus (SCLE), manifested by annular or polycyclic, photodistributed erythematous and scaling lesions, has been reported following",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    in a few cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/50\">",
"     50",
"    </a>",
"    ] and with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/51\">",
"     51",
"    </a>",
"    ]. While phototoxicity may play a role in initiating or sustaining active SCLE, the pathogenesis also involves autoimmunity. This is supported by the presence of deposits of IgG and complement components on epidermal keratinocytes, immunohistopathologic findings that are identical to those found in idiopathic disease. Another shared feature of drug-induced and idiopathic SCLE is the presence of",
"    <span class=\"nowrap\">",
"     anti-Ro/SSA",
"    </span>",
"    antibodies in a majority of cases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/33/36378?source=see_link&amp;anchor=H7#H7\">",
"     \"Mucocutaneous manifestations of systemic lupus erythematosus\", section on 'Subacute cutaneous lupus erythematosus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Scleroderma-like changes, consisting of edema, tightening, and induration of the skin on the trunk and extremities, have been reported in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/52\">",
"     52",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/53\">",
"     53",
"    </a>",
"    ], and were seen in five patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/54\">",
"     54",
"    </a>",
"    ]. The serologic workup for scleroderma was negative in these five patients, and the changes resolved following discontinuation of the drug. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/5/43095?source=see_link\">",
"     \"Diagnosis and differential diagnosis of systemic sclerosis (scleroderma) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     RADIATION RECALL AND ENHANCEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Radiation recall dermatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation recall dermatitis (RRD) is an inflammatory skin reaction that develops in an area of previously irradiated skin after administration of certain promoting agents; most cases have been associated with chemotherapy. There may be a long interval between the administration of the causative agent and the appearance of RRD.",
"   </p>",
"   <p>",
"    RRD was originally described with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/21/14679?source=see_link\">",
"     dactinomycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/55\">",
"     55",
"    </a>",
"    ]. Since then, a number of other drugs have also been associated with this phenomenon (",
"    <a class=\"graphic graphic_table graphicRef77210 \" href=\"mobipreview.htm?34/32/35340\">",
"     table 4",
"    </a>",
"    ), particularly anthracyclines and anthracycline-like drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/56-59\">",
"     56-59",
"    </a>",
"    ]. The frequency of these reactions is unclear.",
"   </p>",
"   <p>",
"    Erythema, which may be painful, is the most common sign [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. Vesiculation, desquamation, and ulceration have also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/1\">",
"     1",
"    </a>",
"    ]. Histologically, epidermal dysplasia, necrotic keratinocytes, and a mixed inflammatory reaction characterize involved areas, with some cases showing psoriasiform dermatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/62\">",
"     62",
"    </a>",
"    ]. Additional dermal changes include fibrosis, vasodilatation, and atypical fibroblasts. Many of these findings mimic the histologic findings of acute severe sunburn or radiation dermatitis.",
"   </p>",
"   <p>",
"    RRD typically occurs with the first dose of the chemotherapy agent or combination. Drug dose appears to be an important factor, as evidenced by one report in which the patient initially received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    27",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    two weeks after radiation therapy with no reaction; administration of a higher dose of the drug 12 days later resulted in RRD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, RRD may also require a minimum threshold radiation dose. In two case reports, patients receiving various doses of radiotherapy and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    had a radiation recall reaction only in those skin sites that had received the highest radiation dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/64,65\">",
"     64,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chemotherapy agents administered by the intravenous (IV) route usually produce RRD more rapidly (range, several minutes to 14 days) than oral agents, which have a longer lag period (range, three days to two months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. The duration of symptoms also differs with drugs administered IV or orally. RRD caused by IV administration usually resolves within two weeks, whereas symptoms caused by orally administered medications may last for several months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of RRD is controversial. An idiosyncratic hypersensitivity reaction has been proposed, with the \"trauma\" of prior radiation therapy sensitizing an area of skin into manifesting an immune reaction when there is little or no systemic activation (akin to the Koebner phenomenon) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/58\">",
"     58",
"    </a>",
"    ]. However, the occurrence of many of these reactions after the first drug exposure argues against an immune mechanism, and defects in DNA repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/69\">",
"     69",
"    </a>",
"    ] as well as toxic drug effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/58\">",
"     58",
"    </a>",
"    ] have also been proposed as causative factors.",
"   </p>",
"   <p>",
"    Dose reduction and the use of corticosteroids have been used as adjunctive measures to prevent recurrence of RRD, although rechallenge with the same agent does not always lead to symptom recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Radiation enhancement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enhancement of the dermatologic toxicity of radiation therapy can occur if a radiosensitizing chemotherapy drug is administered concurrently or within one week of radiation therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/1\">",
"     1",
"    </a>",
"    ]. The drugs that have been associated with radiation enhancement (also called radiation sensitization) are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef77210 \" href=\"mobipreview.htm?34/32/35340\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The synergistic interaction between chemotherapy and radiation is exploited clinically in situations in which concurrent chemotherapy and radiation are administered to enhance antitumor effect (eg, concomitant 5-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    and radiation therapy for many gastrointestinal tumors). Since these radiation fields are typically deep within the body, enhanced skin toxicity is usually not a significant problem. Skin toxicity is seen more commonly with superficial radiation fields. As an example, the combination of breast or chest wall irradiation concurrent with adjuvant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    is generally avoided in women with breast cancer because of the possibility of enhanced dermatotoxicity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37961?source=see_link&amp;anchor=H1404371166#H1404371166\">",
"     \"Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer\", section on 'Sequencing chemotherapy and radiation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radiation enhancement involving the skin resembles RRD, with painful erythema, edema, superficial desquamation, and if severe, erosions (wet desquamation). Similar to RRD, the eruption usually localizes to the irradiated field, but there may be local extension to unirradiated areas. Histologically, epidermal dysplasia, necrotic keratinocytes, and a mixed inflammatory reaction characterize involved areas, with some cases showing psoriasiform dermatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Susceptibility to this effect decreases as the time between administration of chemotherapy and radiation therapy lengthens. In one report, superficial desquamation occurred in 50 percent of patients with lung cancer who received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    within five days of radiation therapy, while no desquamative reactions occurred when the interval between radiation and chemotherapy was increased to three weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/71,72\">",
"     71,72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Possible explanations for the synergy between radiation and chemotherapy include increased blood supply and cellular reoxygenation to the tissue, interference with repair of radiation damage, competition for repair enzymes, and an increased percentage of cells in sensitive phases of the cell cycle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/73\">",
"     73",
"    </a>",
"    ]. For example,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    arrests cell division in the G2 and M phases of the cell cycle, when cells are the most susceptible to ionizing radiation injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The eruption is usually self-limiting, resolving over a period of days to months. Treatment of radiation enhancement reactions is symptomatic and includes the application of cold compresses, local wound care to prevent infection, and the avoidance of trauma, irritation, heat, and ultraviolet (UV) light. Long-term sequelae may include skin atrophy, fibrosis, and telangiectasias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     ACRAL ERYTHEMA (HAND-FOOT SKIN REACTION)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acral erythema has been known by a variety of terms including palmar-plantar erythrodysesthesia, hand-foot skin reaction, hand-foot syndrome, toxic erythema of the palms and soles, and Burgdorf's reaction. Since the original report in patients receiving high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    for acute leukemia, acral erythema has been described most often in patients receiving cytarabine,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/13/10458?source=see_link\">",
"     pegylated liposomal doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    , or 5-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    (5-FU), although many other drugs have been implicated (",
"    <a class=\"graphic graphic_table graphicRef78089 \" href=\"mobipreview.htm?42/11/43195\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/75-78\">",
"     75-78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multitargeted tyrosine kinase inhibitors such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    , and others that target angiogenesis are also associated with a high incidence of a hand-foot skin reaction, but the clinical and histologic patterns differ from the classic acral erythema that develops with conventional cytotoxic agents (",
"    <a class=\"graphic graphic_table graphicRef74634 \" href=\"mobipreview.htm?7/45/7900\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/79-81\">",
"     79-81",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35834?source=see_link&amp;anchor=H9#H9\">",
"     \"Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy\", section on 'Sorafenib and sunitinib'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Affected patients initially complain of a tingling sensation in the palms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    soles. This is followed by edema and tender, symmetrical erythema, which is most pronounced over the fat pads of the distal phalanges (",
"    <a class=\"graphic graphic_picture graphicRef79857 graphicRef77501 \" href=\"mobipreview.htm?20/33/21016\">",
"     picture 3A-B",
"    </a>",
"    ). Skip areas may occur, as can extension to the dorsal surfaces of the extremities. Although rare, acral erythema involving the penis and scrotum has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Affected areas may develop pallor, blistering, and desquamation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/83-85\">",
"     83-85",
"    </a>",
"    ]. A particularly severe bullous variant, progressing to full-thickness epidermal necrosis and sloughing, has been reported following",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    or high-dose intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , particularly in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/86-91\">",
"     86-91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acral erythema is a painful condition, and it may limit daily activities such as walking or grasping objects. Functional impairment is a component of the grading system for severity of hand-foot syndrome (",
"    <a class=\"graphic graphic_table graphicRef73474 \" href=\"mobipreview.htm?13/20/13643\">",
"     table 7",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    One potential consequence of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    -associated chronic acral erythema is the loss of fingerprints [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/92\">",
"     92",
"    </a>",
"    ]. Patients on long-term therapy should be advised of this potential adverse effect, since it may be an impediment in situations in which fingerprint identification is necessary (eg, international travel). It is unknown whether this side effect can occur with other drugs.",
"   </p>",
"   <p>",
"    A presumed variant of acral erythema, termed fixed erythrodysesthesia plaque (FEP), is characteristic of IV injections of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]. This lesion develops as a fixed, solitary plaque proximal to the infusion site that does not involve the palms or soles. It usually resolves with desquamation, leaving an area of hyperpigmented skin five to six weeks later.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least in the case of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    , acral erythema is dose related. Furthermore, drug formulation and administration schedules that result in sustained serum levels of cytotoxic agents are more frequently associated with acral erythema, as evidenced by the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The liposome-encapsulated form of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      is associated with a higher incidence of acral erythema than the nonencapsulated form, particularly when initial doses greater than 40",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      are administered [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/95\">",
"       95",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      While acral erythema is uncommon when 5-FU is administered as a bolus injection, it is often the dose-limiting toxicity with prolonged infusions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The incidence of acral erythema with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      (an oral fluoropyrimidine that is converted in vivo to 5-FU, providing prolonged tissue exposure) is nearly 60 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/96\">",
"       96",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Histology and pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histologic changes of acral erythema are nonspecific. A vacuolar interface dermatitis with necrotic keratinocytes is most commonly seen, with superficial dermal edema and a perivascular lymphocytic infiltrate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/97,98\">",
"     97,98",
"    </a>",
"    ]. The differential diagnosis includes graft-versus-host disease (GVHD, in the appropriate clinical setting) and erythema multiforme. The distinction of acral erythema from GVHD is an important one since the treatments are distinct. Unfortunately, a biopsy may not be able to distinguish between these entities in a clinically relevant timeframe. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/22/25960?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease\", section on 'Skin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/25/23962?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations, diagnosis, and grading of chronic graft-versus-host disease\", section on 'Mucocutaneous manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathogenesis of acral erythema is not well understood. A direct toxic effect of the chemotherapeutic agent on eccrine coils (which are in highest density on the palms and soles) is most often proposed, although there is no direct evidence to support this theory, and microscopic evidence of damage to the eccrine sweat glands or ducts is only infrequently reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/99,100\">",
"     99,100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Others suggest that acral erythema represents a mild form of acute graft-versus-host disease, although evidence to substantiate this viewpoint is lacking. Furthermore, acral erythema most often develops in patients who have neither undergone hematopoietic cell transplantation nor received blood products [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/1\">",
"     1",
"    </a>",
"    ]. Finally, the occasional co-occurrence of facial",
"    <span class=\"nowrap\">",
"     erythema/edema,",
"    </span>",
"    papular rash and fever have led some to view this as a type I (IgE-mediated) allergic reaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    , at least some data suggest that expression of the capecitabine-activating enzyme thymidine phosphorylase is significantly greater in the skin of the palms as compared to skin on the lower back, providing higher tissue levels of the active moiety to this area [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/97\">",
"     97",
"    </a>",
"    ]. Furthermore, the proliferative rate of epidermal basal cells in the palm was also higher as compared to skin from the back, suggesting that palmar skin might be more sensitive to the local action of cytotoxic drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Treatment and prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main treatment for acral erythema is drug cessation and symptomatic treatment to provide analgesia, lessen edema, and prevent superinfection. Acral erythema usually resolves within two to four weeks after discontinuation of the causative agent, but healing frequently involves superficial desquamation of involved areas. There are usually no long-term sequelae although palmoplantar keratoderma may develop as a result of long-standing acral erythema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Support for a variety of other approaches to treat or prevent acral erythema come from small series, although none has been proven in randomized trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Local application of cold during therapy by applying ice packs to the wrists and ankles may help by decreasing blood flow to the hands and feet [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/103,104\">",
"       103,104",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Treatment with topical 99 percent DMSO four times daily for 14 days led to resolution of symptoms over one to three weeks in two patients who had been receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/13/10458?source=see_link\">",
"       pegylated liposomal doxorubicin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/105\">",
"       105",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A benefit for oral corticosteroids in reducing the frequency of acral erythema was suggested by two small series [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/106,107\">",
"       106,107",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Early studies suggesting symptomatic improvement from pyridoxine in patients with acral erythema [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/108,109\">",
"       108,109",
"      </a>",
"      ] led to interest in the use of this vitamin as a preventive agent. However, in two separate phase III trials, in which patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      -based chemotherapy or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/13/10458?source=see_link\">",
"       pegylated liposomal doxorubicin",
"      </a>",
"      were randomly assigned to either pyridoxine (200 mg daily) or placebo, pyridoxine did not prevent this complication or lessen its severity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/110,111\">",
"       110,111",
"      </a>",
"      ]. In addition, pyridoxine did not ameliorate symptoms among placebo-treated patients who received open-label pyridoxine after the development of grade 2 or 3 acral erythema [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/110\">",
"       110",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients who develop severe acral erythema (particularly grade 3, (",
"    <a class=\"graphic graphic_table graphicRef73474 \" href=\"mobipreview.htm?13/20/13643\">",
"     table 7",
"    </a>",
"    )), subsequent chemotherapy doses must be reduced to avoid recurrence. Dose modification does not appear to impair drug efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/112\">",
"     112",
"    </a>",
"    ]. Based upon the severity of the reaction, and the hazard of recurrence, it may be necessary to discontinue therapy entirely, and switch to an alternative regimen, if one is available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     NEUTROPHILIC ECCRINE HIDRADENITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutrophilic eccrine hidradenitis (NEH) is a reactive disorder that may occur in association with malignancy (with or without chemotherapy), infections, and certain medications.",
"   </p>",
"   <p>",
"    The original description of drug-induced NEH was in a patient receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    for acute myeloid leukemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/113\">",
"     113",
"    </a>",
"    ]. Since then, a variety of chemotherapeutic agents have been associated with this entity (",
"    <a class=\"graphic graphic_table graphicRef50193 \" href=\"mobipreview.htm?4/29/4571\">",
"     table 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/1,114,115\">",
"     1,114,115",
"    </a>",
"    ]. In addition, NEH has been reported in HIV patients, after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    use, as a paraneoplastic eruption in patients with malignancy who are not receiving chemotherapy (probably as a variant of Sweet syndrome), and as an idiopathic condition in children. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/43/30393?source=see_link&amp;anchor=H29#H29\">",
"     \"Neutrophilic dermatoses\", section on 'Neutrophilic eccrine hidradenitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/18/21802?source=see_link&amp;anchor=H3208878#H3208878\">",
"     \"Cutaneous manifestations of internal malignancy\", section on 'Sweet syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients present with the eruption one to two weeks after therapy with the offending agent. The clinical presentation is nonspecific. Lesions are typically asymptomatic, erythematous, edematous plaques but may be purpuric and painful. They can be located on the extremities, trunk, and face, including the periorbital region, where severe lesions may mimic cellulitis. Generalized, erythema multiforme-like lesions have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/116\">",
"     116",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/43/30393?source=see_link&amp;anchor=H29#H29\">",
"     \"Neutrophilic dermatoses\", section on 'Neutrophilic eccrine hidradenitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In all cases of suspected NEH, a biopsy should be performed, since the clinical picture is nonspecific, while the histopathologic presentation is distinct. In most cases, neutrophils surround the eccrine glands, and a vacuolar interface dermatitis is visible in glands and ducts, along with necrosis of lining cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/117\">",
"     117",
"    </a>",
"    ]. Epidermal keratinocyte atypia is a common associated finding in cases that are related to chemotherapy administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/118\">",
"     118",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If chemotherapy-induced neutropenia is present, neutrophils may be absent on histologic examination. However, other characteristic findings, such as eccrine gland necrosis, are still identifiable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The natural history is that of spontaneous resolution in one to two weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/119\">",
"     119",
"    </a>",
"    ]. While the reaction is self-limited and resolves without therapy, some studies support the use of systemic corticosteroids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/120\">",
"     120",
"    </a>",
"    ]. However, efficacy has not been established in controlled, randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/120\">",
"     120",
"    </a>",
"    ]. One case report suggests that oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    may be useful for prophylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/121\">",
"     121",
"    </a>",
"    ]. The majority of patients with NEH will develop the same eruption with retreatment.",
"   </p>",
"   <p>",
"    The cause of NEH in patients receiving chemotherapy is unknown. It is postulated that a high concentration of the drug in sweat has a direct toxic effect on the eccrine glands [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/117,122\">",
"     117,122",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     EXANTHEMATOUS ERUPTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Exanthematous (morbilliform) rashes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide variety of chemotherapy drugs have been associated with a mild nonspecific exanthematous drug eruption, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    . Morbilliform eruptions, also called &ldquo;maculopapular&rdquo; (",
"    <a class=\"graphic graphic_picture graphicRef54205 graphicRef70062 \" href=\"mobipreview.htm?36/36/37445\">",
"     picture 4A-B",
"    </a>",
"    ) are characterized by monomorphic erythematous papules and are usually classified as \"drug rash\" in package inserts and literature references. The similarity of these rashes to those described for many other drugs underscores the importance of evaluating all medications taken by the patient before concluding that the rash is caused by the chemotherapy agent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/50/24360?source=see_link\">",
"     \"Exanthematous (morbilliform) drug eruption\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adverse skin reactions with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    may include an erythematous papular rash or erythematous nodules or plaques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/54,123\">",
"     54,123",
"    </a>",
"    ]. In one study, rash affected 26 of 140 patients (19 percent), the majority during the third or fourth course of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/124\">",
"     124",
"    </a>",
"    ]. Six patients underwent biopsy, which showed a small vessel necrotizing vasculitis.",
"   </p>",
"   <p>",
"    The management of patients with a chemotherapy drug rash is dictated by the severity of the reaction as well as the clinical circumstances surrounding the use of the individual chemotherapy agent. Pertinent issues include whether the offending agent is being used with curative versus palliative intent and whether an adequate substitute from another drug class is available. In mild cases, treatment with topical steroids is usually recommended, without specific modification of the chemotherapy regimen.",
"   </p>",
"   <p>",
"    Pretreatment with corticosteroids is not usually recommended to prevent or diminish a chemotherapy-induced drug rash. One exception to this general rule is the drug",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"     pemetrexed",
"    </a>",
"    , a folate analog used in the treatment of mesothelioma and non-small cell lung cancer. In an early phase II study, pemetrexed was associated with a papular skin rash in 66 percent of treated patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/125\">",
"     125",
"    </a>",
"    ]. The rash was sometimes associated with edema",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    desquamation, and responsive to corticosteroid treatment.",
"   </p>",
"   <p>",
"    Subsequent phase I, II, and III trials have noted a much lower incidence (less than 20 percent) and severity of skin rash, attributed to the routine use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    4 mg twice daily for three days starting the day before treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/126-129\">",
"     126-129",
"    </a>",
"    ]. As a result, premedication with this schedule of dexamethasone has become a standard practice for patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"     pemetrexed",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/127\">",
"     127",
"    </a>",
"    ]. Whether fewer doses would suffice is unknown.",
"   </p>",
"   <p>",
"    At least one case of urticarial vasculitis has been attributed to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"     pemetrexed",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/130\">",
"     130",
"    </a>",
"    ]. However, whether this is the mechanism underlying the more frequently observed papular skin rash is unclear.",
"   </p>",
"   <p>",
"    Conjunctivitis, periorbital edema, and lower extremity edema and erythema have also been reported in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"     pemetrexed",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/131,132\">",
"     131,132",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Fixed drug eruptions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fixed drug eruptions are typically characterized by the rapid formation of a solitary macule, plaque, or bulla after drug exposure in a sensitized individual, although multiple or diffuse lesions can be observed in rare cases. The cytotoxic drugs most commonly associated with a fixed drug eruption are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef54060 \" href=\"mobipreview.htm?0/7/119\">",
"     table 9",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/17/41241?source=see_link&amp;anchor=H11#H11\">",
"     \"Drug eruptions\", section on 'Fixed drug eruption'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The characteristic early lesion is a sharply demarcated erythematous round to oval macule, which develops from 30 minutes to eight hours after drug exposure and arises in the same location after each exposure. One-half occur on the oral or genital mucosa. Within hours, the lesion becomes edematous, forming a plaque, which may evolve to bulla and eventually to erosion. Lesions persist if the drug is continued, but they resolve within days to weeks after drug is discontinued.",
"   </p>",
"   <p>",
"    Post-inflammatory hyperpigmentation may take months to resolve. No specific treatments are recommended other than discontinuation of the offending drug, although topical steroids instituted early after lesion development may help to reduce post-inflammatory hyperpigmentation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Diffuse erythema and exfoliative dermatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffuse erythema has been described with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/133\">",
"     133",
"    </a>",
"    ]. Many of these eruptions are mild and self-limited, and they do not proceed to exfoliation. Drugs that are more likely to be associated with exfoliative dermatitis include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , and rarely, intravesical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/134-137\">",
"     134-137",
"    </a>",
"    ]. At least some of these cases are thought to be immune-mediated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Erythema multiforme, SJS, and toxic epidermal necrolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relatively few antineoplastic agents cause the blistering dermatoses erythema multiforme, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN, (",
"    <a class=\"graphic graphic_picture graphicRef66134 \" href=\"mobipreview.htm?17/63/18419\">",
"     picture 5",
"    </a>",
"    )). Specific agents reported to cause these reactions are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef80544 \" href=\"mobipreview.htm?38/2/38956\">",
"     table 10",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Erythema multiforme is characterized by the presence of targetoid lesions on the palms and soles. By definition, target lesions consist of three rings or \"zones\": a central dusky zone surrounded by an edematous pale ring, and surrounded by macular erythema. Classical erythema multiforme is associated with herpes virus infection, although a similar reaction pattern has been described in idiopathic and drug-induced cases, contact dermatitis, and connective tissue diseases such as lupus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/17/41241?source=see_link\">",
"     \"Drug eruptions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to erythema multiforme, SJS and TEN more commonly represent adverse reactions to medications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/29/17882?source=see_link\">",
"     \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      SJS is a serious eruption in which atypical targetoid lesions, blisters, and desquamative areas occur involving less than 30 percent of the body surface area and at least two mucosal surfaces. In contrast to target lesions of erythema multiforme, the appearance of atypical target lesions in SJS is more variable, typically consisting of a central dusky zone on a background of erythema, and lacking the second edematous zone.",
"     </li>",
"     <li>",
"      TEN is a severe, life-threatening complication of drug therapy, involving greater than 30 percent body surface area. When it occurs, it warrants immediate and permanent discontinuation of the offending agent. Most of these patients require inpatient management, often in a burn unit because of extensive desquamation and subsequent risk for hyponatremic dehydration and sepsis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whether drug-induced erythema multiforme can evolve into SJS or TEN is controversial, since these reactions are thought to reflect different underlying mechanisms of immune-mediated skin injury. Type III hypersensitivity reactions (",
"    <a class=\"graphic graphic_table graphicRef71375 \" href=\"mobipreview.htm?13/23/13692\">",
"     table 1",
"    </a>",
"    ), which result from formation and tissue deposition of antigen-antibody complexes, are thought to be responsible for drug-induced erythema multiforme [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Other immune-mediated mechanisms have been implicated in TEN, such as the activation of Fas ligand [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/138\">",
"     138",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who develop SJS or TEN should never be reexposed to the causative drug because of the risk of a fatal recurrence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     MISCELLANEOUS REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment-induced leg ulcers occasionally occur in patients taking long-term",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    for myeloproliferative disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/139-142\">",
"     139-142",
"    </a>",
"    ]. Lesions are most commonly located near the malleoli, and are characteristically painful. The primary mechanism of ulcer formation may involve hydroxyurea-induced inhibition of the synthesis (S) phase of the cell cycle, leading to basal keratinocyte damage and the suppression of collagen synthesis. Discontinuation of therapy is necessary for healing; ulcers recur if treatment is reinitiated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/142\">",
"     142",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are many other rare cutaneous reactions that have been attributed to chemotherapy agents, including Sj&ouml;gren's syndrome, dermatomyositis, Raynaud's phenomenon, reactivation of varicella-zoster infection, porphyria, and a blistering disorder characterized as a paraneoplastic pemphigus-like phenomenon with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/7/36986/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/44/18121?source=see_link\">",
"     \"Paraneoplastic pemphigus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A partial list of such reactions and the associated chemotherapeutic agents can be found in the following table (",
"    <a class=\"graphic graphic_table graphicRef51026 \" href=\"mobipreview.htm?16/50/17196\">",
"     table 11",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25381708\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Systemic and local application of conventional chemotherapy agents in patients with cancer can cause a number of changes in the skin, mucous membranes, hair, and nails. Some of these changes are immuno-mediated hypersensitivity reactions, including urticaria and angioedema, erythema multiforme, vasculitis, or contact dermatitis (",
"      <a class=\"graphic graphic_table graphicRef71375 \" href=\"mobipreview.htm?13/23/13692\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Immune-mediated hypersensitivity reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pigmentary changes involving the skin, nails, and mucous membranes are common in patients receiving cytotoxic drugs, particularly alkylating agents and antitumor antibiotics (",
"      <a class=\"graphic graphic_table graphicRef60304 \" href=\"mobipreview.htm?33/43/34492\">",
"       table 2",
"      </a>",
"      ). The hyperpigmentation can be localized or diffuse, sometimes with distinctive patterns (eg, serpentine, flagellate). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pigmentary changes'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Nail changes, such as hyperpigmentation and onycholysis (",
"      <a class=\"graphic graphic_picture graphicRef63373 \" href=\"mobipreview.htm?10/46/10991\">",
"       picture 2",
"      </a>",
"      ), sometimes associated with inflammatory involvement of the periungual tissues, may be induced by many medications, including alkylating agents, taxanes, antimetabolites, anthracyclines, and antitumor antibiotics (",
"      <a class=\"graphic graphic_table graphicRef72242 \" href=\"mobipreview.htm?33/22/34156\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Nail disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Photosensitivity reactions, including photoallergic and phototoxic reactions, have been associated with a variety of chemotherapy agents. Photoreactivation and photoenhancement reactions have been reported with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      and taxanes. The combination of some agents such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/43/37559?source=see_link\">",
"       mercaptopurine",
"      </a>",
"      with ultraviolet light may induce photoonycholysis. &nbsp;(See",
"      <a class=\"local\" href=\"#H14\">",
"       'Photosensitivity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Subacute cutaneous lupus erythematosus, manifested by annular or polycyclic, photodistributed erythematous and scaling lesions, has been reported in a few cases following",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Subacute cutaneous lupus erythematosus and scleroderma-like changes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Radiation recall dermatitis (RRD) is an inflammatory skin reaction that develops in an area of previously irradiated skin after administration of several chemotherapy agents (",
"      <a class=\"graphic graphic_table graphicRef77210 \" href=\"mobipreview.htm?34/32/35340\">",
"       table 4",
"      </a>",
"      ). Some drugs may enhance the dermatologic toxicity of radiation therapy when administered concurrently or within one week of radiation therapy. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Radiation recall and enhancement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acral erythema (",
"      <a class=\"graphic graphic_picture graphicRef79857 graphicRef77501 \" href=\"mobipreview.htm?20/33/21016\">",
"       picture 3A-B",
"      </a>",
"      ) occurs most often in patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/13/10458?source=see_link\">",
"       pegylated liposomal doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"      , although many other drugs have been implicated (",
"      <a class=\"graphic graphic_table graphicRef78089 \" href=\"mobipreview.htm?42/11/43195\">",
"       table 5",
"      </a>",
"      ). Acral erythema is dose-related and usually resolves within two to four weeks after discontinuation of the causative agent with superficial desquamation of involved areas. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Acral erythema (hand-foot skin reaction)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neutrophilic eccrine hidradenitis presents with erythematous, edematous plaques in patients with malignancy (with or without chemotherapy), infections, or receiving a variety of chemotherapeutic agents (",
"      <a class=\"graphic graphic_table graphicRef50193 \" href=\"mobipreview.htm?4/29/4571\">",
"       table 8",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Neutrophilic eccrine hidradenitis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/43/30393?source=see_link&amp;anchor=H29#H29\">",
"       \"Neutrophilic dermatoses\", section on 'Neutrophilic eccrine hidradenitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Exanthematous eruptions, including morbilliform rashes (",
"      <a class=\"graphic graphic_picture graphicRef54205 graphicRef70062 \" href=\"mobipreview.htm?36/36/37445\">",
"       picture 4A-B",
"      </a>",
"      ) and fixed drug eruptions, may occur in association with many chemotherapeutic agents (",
"      <a class=\"graphic graphic_table graphicRef54060 \" href=\"mobipreview.htm?0/7/119\">",
"       table 9",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Exanthematous (morbilliform) rashes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A few antineoplastic agents may cause blistering and exfoliative dermatoses (ie, erythema multiforme, Steven-Johnson syndrome [SJS], or toxic epidermal necrolysis [TEN]) (",
"      <a class=\"graphic graphic_table graphicRef80544 \" href=\"mobipreview.htm?38/2/38956\">",
"       table 10",
"      </a>",
"      ). Toxic epidermal necrolysis is a rare severe, life-threatening complication of drugs, including cytotoxic chemotherapy (",
"      <a class=\"graphic graphic_picture graphicRef66134 \" href=\"mobipreview.htm?17/63/18419\">",
"       picture 5",
"      </a>",
"      ). Patients who develop SJS or TEN should never be reexposed to the causative drug because of the risk of a fatal recurrence. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Erythema multiforme, SJS, and toxic epidermal necrolysis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/29/17882?source=see_link\">",
"       \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rare reactions, including leg ulcers, Sj&ouml;gren syndrome, dermatomyositis, Raynaud phenomenon, reactivation of varicella-zoster infection, porphyria, and a paraneoplastic pemphigus-like phenomenon have been associated with several chemotherapeutic agents (",
"      <a class=\"graphic graphic_table graphicRef51026 \" href=\"mobipreview.htm?16/50/17196\">",
"       table 11",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Miscellaneous reactions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/1\">",
"      Susser WS, Whitaker-Worth DL, Grant-Kels JM. Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol 1999; 40:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/2\">",
"      Asnis LA, Gaspari AA. Cutaneous reactions to recombinant cytokine therapy. J Am Acad Dermatol 1995; 33:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/3\">",
"      Remlinger KA. Cutaneous reactions to chemotherapy drugs: the art of consultation. Arch Dermatol 2003; 139:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/4\">",
"      Payne AS, James WD, Weiss RB. Dermatologic toxicity of chemotherapeutic agents. Semin Oncol 2006; 33:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/5\">",
"      Weiss RB, Baker JR Jr. Hypersensitivity reactions from antineoplastic agents. Cancer Metastasis Rev 1987; 6:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/6\">",
"      Spiegel RJ. The acute toxicities of chemotherapy. Cancer Treat Rev 1981; 8:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/7\">",
"      Foulc P, Evrard V, Dalac S, et al. Evaluation of a 1-h exposure time to mechlorethamine in patients undergoing topical treatment. Br J Dermatol 2002; 147:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/8\">",
"      Est&egrave;ve E, Bagot M, Joly P, et al. A prospective study of cutaneous intolerance to topical mechlorethamine therapy in patients with cutaneous T-cell lymphomas. French Study Group of Cutaneous Lymphomas. Arch Dermatol 1999; 135:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/9\">",
"      Veelken H, Sklar JL, Wood GS. Detection of low-level tumor cells in allergic contact dermatitis induced by mechlorethamine in patients with mycosis fungoides. J Invest Dermatol 1996; 106:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/10\">",
"      Singal R, Tunnessen WW Jr, Wiley JM, Hood AF. Discrete pigmentation after chemotherapy. Pediatr Dermatol 1991; 8:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/11\">",
"      Piraccini BM, Iorizzo M. Drug reactions affecting the nail unit: diagnosis and management. Dermatol Clin 2007; 25:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/12\">",
"      Jain V, Bhandary S, Prasad GN, Shenoi SD. Serpentine supravenous streaks induced by 5-fluorouracil. J Am Acad Dermatol 2005; 53:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/13\">",
"      Piraccini BM, Tosti A. Drug-induced nail disorders: incidence, management and prognosis. Drug Saf 1999; 21:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/14\">",
"      Baran R, Laugier P. Melanonychia induced by topical 5-fluorouracil. Br J Dermatol 1985; 112:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/15\">",
"      Pujol RM, Rocamora V, Lopez-Pousa A, et al. Persistent supravenous erythematous eruption: a rare local complication of intravenous 5-fluorouracil therapy. J Am Acad Dermatol 1998; 39:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/16\">",
"      Korbitz, BC, Reiquam, CW. Busulfan in chronic granulocytic leukemia, a spectrum of clinical considerations. Clin Med 1969; 76:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/17\">",
"      Bandini G, Belardinelli A, Rosti G, et al. Toxicity of high-dose busulphan and cyclophosphamide as conditioning therapy for allogeneic bone marrow transplantation in adults with haematological malignancies. Bone Marrow Transplant 1994; 13:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/18\">",
"      Lotem M, Hubert A, Lyass O, et al. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol 2000; 136:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/19\">",
"      Issaivanan M, Mitu PS, Manisha C, Praveen K. Cutaneous manifestations of hydroxyurea therapy in childhood: case report and review. Pediatr Dermatol 2004; 21:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/20\">",
"      Aste N, Fumo G, Contu F, et al. Nail pigmentation caused by hydroxyurea: report of 9 cases. J Am Acad Dermatol 2002; 47:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/21\">",
"      Al-Lamki Z, Pearson P, Jaffe N. Localized cisplatin hyperpigmentation induced by pressure. A case report. Cancer 1996; 77:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/22\">",
"      Bronner AK, Hood AF. Cutaneous complications of chemotherapeutic agents. J Am Acad Dermatol 1983; 9:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/23\">",
"      Hendrix JD Jr, Greer KE. Cutaneous hyperpigmentation caused by systemic drugs. Int J Dermatol 1992; 31:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/24\">",
"      Rosman IS, Lloyd BM, Hayashi RJ, Bayliss SJ. Cutaneous effects of thiotepa in pediatric patients receiving high-dose chemotherapy with autologous stem cell transplantation. J Am Acad Dermatol 2008; 58:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/25\">",
"      Schulte-Huermann P, Zumdick M, Ruzicka T. Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 (Ki-1)-positive anaplastic large-cell lymphoma. Dermatology 1995; 191:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/26\">",
"      Baselga E, Drolet BA, Casper J, Esterly NB. Chemotherapy-associated supravenous hyperpigmentation. Dermatology 1996; 192:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/27\">",
"      Todkill D, Taibjee S, Borg A, Gee BC. Flagellate erythema due to bleomycin. Br J Haematol 2008; 142:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/28\">",
"      Mowad CM, Nguyen TV, Elenitsas R, Leyden JJ. Bleomycin-induced flagellate dermatitis: a clinical and histopathological review. Br J Dermatol 1994; 131:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/29\">",
"      Wheeland RG, Burgdorf WH, Humphrey GB. The flag sign of chemotherapy. Cancer 1983; 51:1356.",
"     </a>",
"    </li>",
"    <li>",
"     Holzberg M. Nail signs of systemic disease. In: Atlas of hair and nails, Hordinsky MK, Sawaya ME, Scher RK (Eds), Churchill Livingstone, Philadelphia 2002. p.59.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/31\">",
"      Alimonti A, Nardoni C, Papaldo P, et al. Nail disorders in a woman treated with ixabepilone for metastatic breast cancer. Anticancer Res 2005; 25:3531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/32\">",
"      Wasner G, Hilpert F, Schattschneider J, et al. Docetaxel-induced nail changes--a neurogenic mechanism: a case report. J Neurooncol 2002; 58:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/33\">",
"      Scott&eacute; F, Banu E, Medioni J, et al. Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot. Cancer 2008; 112:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/34\">",
"      Scott&eacute; F, Tourani JM, Banu E, et al. Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol 2005; 23:4424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/35\">",
"      Usuki A, Funasaka Y, Oka M, Ichihashi M. Tegafur-induced photosensitivity--evaluation of provocation by UVB irradiation. Int J Dermatol 1997; 36:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/36\">",
"      Alley E, Green R, Schuchter L. Cutaneous toxicities of cancer therapy. Curr Opin Oncol 2002; 14:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/37\">",
"      DeSpain JD. Dermatologic toxicity of chemotherapy. Semin Oncol 1992; 19:501.",
"     </a>",
"    </li>",
"    <li>",
"     Smoller BR, Horn TD. Chemotherapy-induced drug eruptions. In: Dermatopathology in systemic disease, Smoller BR, Horn TD (Eds), Oxford University Press, New York 2001. p.298.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/39\">",
"      Fujimoto M, Kikuchi K, Imakado S, Furue M. Photosensitive dermatitis induced by flutamide. Br J Dermatol 1996; 135:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/40\">",
"      Leroy D, Dompmartin A, Szczurko C. Flutamide photosensitivity. Photodermatol Photoimmunol Photomed 1996; 12:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/41\">",
"      Korossy KS, Hood AF. Methotrexate reactivation of sunburn reaction. Arch Dermatol 1981; 117:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/42\">",
"      Guzzo C, Kaidby K. Recurrent recall of sunburn by methotrexate. Photodermatol Photoimmunol Photomed 1995; 11:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/43\">",
"      Williams BJ, Roth DJ, Callen JP. Ultraviolet recall associated with etoposide and cyclophosphamide therapy. Clin Exp Dermatol 1993; 18:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/44\">",
"      Andersen KE, Lindskov R. Recall of UVB-induced erythema in breast cancer patient receiving multiple drug chemotherapy. Photodermatol 1984; 1:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/45\">",
"      Ee HL, Yosipovitch G. Photo recall phenomenon: an adverse reaction to taxanes. Dermatology 2003; 207:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/46\">",
"      Badger J, Kang S, Uzieblo A, Srinivas S. Double diagnosis in cancer patients and cutaneous reaction related to gemcitabine: CASE 3. Photo therapy recall with gemcitabine following ultraviolet B treatment. J Clin Oncol 2005; 23:7224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/47\">",
"      Markman M, Kulp B, Peterson G. Grade 3 liposomal-doxorubicin-induced skin toxicity in a patient following complete resolution of moderately severe sunburn. Gynecol Oncol 2004; 94:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/48\">",
"      Gould JW, Mercurio MG, Elmets CA. Cutaneous photosensitivity diseases induced by exogenous agents. J Am Acad Dermatol 1995; 33:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/49\">",
"      Baran R, Juhlin L. Photoonycholysis. Photodermatol Photoimmunol Photomed 2002; 18:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/50\">",
"      Chen M, Crowson AN, Woofter M, et al. Docetaxel (taxotere) induced subacute cutaneous lupus erythematosus: report of 4 cases. J Rheumatol 2004; 31:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/51\">",
"      Weger W, Kr&auml;nke B, Gerger A, et al. Occurrence of subacute cutaneous lupus erythematosus after treatment with fluorouracil and capecitabine. J Am Acad Dermatol 2008; 59:S4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/52\">",
"      Passiu G, Cauli A, Atzeni F, et al. Bleomycin-induced scleroderma: report of a case with a chronic course rather than the typical acute/subacute self-limiting form. Clin Rheumatol 1999; 18:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/53\">",
"      Bessis D, Guillot B, Legouffe E, Guilhou JJ. Gemcitabine-associated scleroderma-like changes of the lower extremities. J Am Acad Dermatol 2004; 51:S73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/54\">",
"      Heidary N, Naik H, Burgin S. Chemotherapeutic agents and the skin: An update. J Am Acad Dermatol 2008; 58:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/55\">",
"      D'ANGIO GJ, FARBER S, MADDOCK CL. Potentiation of x-ray effects by actinomycin D. Radiology 1959; 73:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/56\">",
"      Camidge R, Price A. Characterizing the phenomenon of radiation recall dermatitis. Radiother Oncol 2001; 59:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/57\">",
"      Schwartz BM, Khuntia D, Kennedy AW, Markman M. Gemcitabine-induced radiation recall dermatitis following whole pelvic radiation therapy. Gynecol Oncol 2003; 91:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/58\">",
"      Camidge R, Price A. Radiation recall dermatitis may represent the Koebner phenomenon. J Clin Oncol 2002; 20:4130; author reply 4130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/59\">",
"      Gzell CE, Carroll SL, Suchowerska N, et al. Radiation recall dermatitis after pre-sensitization with pegylated liposomal doxorubicin. Cancer Invest 2009; 27:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/60\">",
"      Shenkier T, Gelmon K. Paclitaxel and radiation-recall dermatitis. J Clin Oncol 1994; 12:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/61\">",
"      Parry BR. Radiation recall induced by tamoxifen. Lancet 1992; 340:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/62\">",
"      Smith KJ, Germain M, Skelton H. Histopathologic features seen with radiation recall or enhancement eruptions. J Cutan Med Surg 2002; 6:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/63\">",
"      Cassady JR, Richter MP, Piro AJ, Jaffe N. Radiation-adriamycin interactions: preliminary clinical observations. Cancer 1975; 36:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/64\">",
"      Yeo W, Leung SF, Johnson PJ. Radiation-recall dermatitis with docetaxel: establishment of a requisite radiation threshold. Eur J Cancer 1997; 33:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/65\">",
"      Stelzer KJ, Griffin TW, Koh WJ. Radiation recall skin toxicity with bleomycin in a patient with Kaposi sarcoma related to acquired immune deficiency syndrome. Cancer 1993; 71:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/66\">",
"      Burstein HJ. Side effects of chemotherapy. Case 1. Radiation recall dermatitis from gemcitabine. J Clin Oncol 2000; 18:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/67\">",
"      Ortmann E, Hohenberg G. Treatment side effects. Case 1. Radiation recall phenomenon after administration of capecitabine. J Clin Oncol 2002; 20:3029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/68\">",
"      Bostr&ouml;m A, Sj&ouml;lin-Forsberg G, Wilking N, Bergh J. Radiation recall--another call with tamoxifen. Acta Oncol 1999; 38:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/69\">",
"      Phillips TL, Fu KK. Quantification of combined radiation therapy and chemotherapy effects on critical normal tissues. Cancer 1976; 37:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/70\">",
"      Castellano D, Hitt R, Cort&eacute;s-Funes H, et al. Side effects of chemotherapy. Case 2. Radiation recall reaction induced by gemcitabine. J Clin Oncol 2000; 18:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/71\">",
"      Greco FA, Brereton HD, Kent H, et al. Adriamycin and enhanced radiation reaction in normal esophagus and skin. Ann Intern Med 1976; 85:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/72\">",
"      Greco FA, Oldham RK. Adriamycin and radiation reactions. Ann Intern Med 1977; 86:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/73\">",
"      O'Rourke ME. Enhanced cutaneous effects in combined modality therapy. Oncol Nurs Forum 1987; 14:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/74\">",
"      Tishler RB, Schiff PB, Geard CR, Hall EJ. Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys 1992; 22:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/75\">",
"      Hoff PM, Valero V, Ibrahim N, et al. Hand-foot syndrome following prolonged infusion of high doses of vinorelbine. Cancer 1998; 82:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/76\">",
"      Eich D, Scharffetter-Kochanek K, Eich HT, et al. Acral erythrodysesthesia syndrome caused by intravenous infusion of docetaxel in breast cancer. Am J Clin Oncol 2002; 25:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/77\">",
"      Ozmen S, Dogru M, Bozkurt C, Kocaoglu AC. Probable cytarabine-induced acral erythema: report of 2 pediatric cases. J Pediatr Hematol Oncol 2013; 35:e11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/78\">",
"      Farr KP, Safwat A. Palmar-plantar erythrodysesthesia associated with chemotherapy and its treatment. Case Rep Oncol 2011; 4:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/79\">",
"      Lacouture ME, Reilly LM, Gerami P, Guitart J. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 2008; 19:1955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/80\">",
"      Autier J, Escudier B, Wechsler J, et al. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol 2008; 144:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/81\">",
"      Chu D, Lacouture ME, Fillos T, Wu S. Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol 2008; 47:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/82\">",
"      Sapp CM, DeSimone P. Palmar-plantar erythrodysesthesia associated with scrotal and penile involvement with capecitabine. Clin Colorectal Cancer 2007; 6:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/83\">",
"      Cohen PR. Acral erythema: a clinical review. Cutis 1993; 51:175.",
"     </a>",
"    </li>",
"    <li>",
"     Hood AF, Haynes HA. Dermatologic complications. In: Cancer Medicine, Holland JF, et al (Eds), Williams &amp; Wilkins, Baltimore  p.3141.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/85\">",
"      Burgdorf WH, Gilmore WA, Ganick RG. Peculiar acral erythema secondary to high-dose chemotherapy for acute myelogenous leukemia. Ann Intern Med 1982; 97:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/86\">",
"      Hellier I, Bessis D, Sotto A, et al. High-dose methotrexate-induced bullous variant of acral erythema. Arch Dermatol 1996; 132:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/87\">",
"      Werchniak AE, Chaffee S, Dinulos JG. Methotrexate-induced bullous acral erythema in a child. J Am Acad Dermatol 2005; 52:S93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/88\">",
"      Ozkaya-Bayazit E, Diz-K&uuml;&ccedil;&uuml;kkaya R, Akasya E, et al. Bullous acral erythema and concomitant pigmentation on the face and occluded skin. J Eur Acad Dermatol Venereol 2000; 14:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/89\">",
"      Azurdia RM, Clark RE, Friedmann PS. Chemotherapy-induced acral erythema (CIAE) with bullous reaction. Clin Exp Dermatol 1999; 24:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/90\">",
"      Podjasek JO, Camilleri MJ. Bullous acral erythema: an additional consideration in the differential diagnosis of pauci-inflammatory subepidermal bullae*. J Cutan Pathol 2012; 39:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/91\">",
"      Ayta&ccedil; S, G&uuml;mr&uuml;k F, Cetin M, et al. Acral erythema with bullous formation: a side effect of chemotherapy in a child with acute lymphoblastic leukemia. Turk J Pediatr 2010; 52:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/92\">",
"      Wong M, Choo SP, Tan EH. Travel warning with capecitabine. Ann Oncol 2009; 20:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/93\">",
"      Chew L, Chuen VS. Cutaneous reaction associated with weekly docetaxel administration. J Oncol Pharm Pract 2009; 15:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/94\">",
"      Chu CY, Yang CH, Yang CY, et al. Fixed erythrodysaesthesia plaque due to intravenous injection of docetaxel. Br J Dermatol 2000; 142:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/95\">",
"      Kim RJ, Peterson G, Kulp B, et al. Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m2) in the treatment of gynecologic cancers. Gynecol Oncol 2005; 97:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/96\">",
"      Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/97\">",
"      Levine LE, Medenica MM, Lorincz AL, et al. Distinctive acral erythema occurring during therapy for severe myelogenous leukemia. Arch Dermatol 1985; 121:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/98\">",
"      Nagore E, Insa A, Sanmart&iacute;n O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management. Am J Clin Dermatol 2000; 1:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/99\">",
"      Baack BR, Burgdorf WH. Chemotherapy-induced acral erythema. J Am Acad Dermatol 1991; 24:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/100\">",
"      Tsuboi H, Yonemoto K, Katsuoka K. A case of bleomycin-induced acral erythema (AE) with eccrine squamous syringometaplasia (ESS) and summary of reports of AE with ESS in the literature. J Dermatol 2005; 32:921.",
"     </a>",
"    </li>",
"    <li>",
"     Weiss RB. Hypersensitivity reactions. In: The Chemotherapy Source Book, 3rd ed, Lippincott, Williams, and Wilkins, Philadelphia 2001. p.442.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/102\">",
"      Jucgl&agrave; A, Sais G, Navarro M, Peyri J. Palmoplantar keratoderma secondary to chronic acral erythema due to tegafur. Arch Dermatol 1995; 131:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/103\">",
"      Molpus KL, Anderson LB, Craig CL, Puleo JG. The effect of regional cooling on toxicity associated with intravenous infusion of pegylated liposomal doxorubicin in recurrent ovarian carcinoma. Gynecol Oncol 2004; 93:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/104\">",
"      Mangili G, Petrone M, Gentile C, et al. Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling. Gynecol Oncol 2008; 108:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/105\">",
"      Lopez AM, Wallace L, Dorr RT, et al. Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia. Cancer Chemother Pharmacol 1999; 44:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/106\">",
"      Drake RD, Lin WM, King M, et al. Oral dexamethasone attenuates Doxil-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies. Gynecol Oncol 2004; 94:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/107\">",
"      Lorusso V, Manzione L, Silvestris N. Role of liposomal anthracyclines in breast cancer. Ann Oncol 2007; 18 Suppl 6:vi70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/108\">",
"      Vukelja SJ, Baker WJ, Burris HA 3rd, et al. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with taxotere. J Natl Cancer Inst 1993; 85:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/109\">",
"      Fabian CJ, Molina R, Slavik M, et al. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest New Drugs 1990; 8:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/110\">",
"      Kang YK, Lee SS, Yoon DH, et al. Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study. J Clin Oncol 2010; 28:3824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/111\">",
"      von Gruenigen V, Frasure H, Fusco N, et al. A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients. Cancer 2010; 116:4735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/112\">",
"      Scheithauer W, Blum J. Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine. Oncology (Williston Park) 2004; 18:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/113\">",
"      Harrist TJ, Fine JD, Berman RS, et al. Neutrophilic eccrine hidradenitis. A distinctive type of neutrophilic dermatosis associated with myelogenous leukemia and chemotherapy. Arch Dermatol 1982; 118:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/114\">",
"      Bailey DL, Barron D, Lucky AW. Neutrophilic eccrine hidradenitis: a case report and review of the literature. Pediatr Dermatol 1989; 6:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/115\">",
"      Margolis DJ, Gross PR. Neutrophilic eccrine hidradenitis: a case report and review of the literature. Cutis 1991; 48:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/116\">",
"      Thorisdottir K, Tomecki KJ, Bergfeld WF, Andresen SW. Neutrophilic eccrine hidradenitis. J Am Acad Dermatol 1993; 28:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/117\">",
"      Brehler R, Reimann S, Bonsmann G, Metze D. Neutrophilic hidradenitis induced by chemotherapy involves eccrine and apocrine glands. Am J Dermatopathol 1997; 19:73.",
"     </a>",
"    </li>",
"    <li>",
"     Smoller BR, Horn TD. Chemotherapy-induced drug eruptions. In: Dermatopathology in systemic disease, Smoller BR, Horn TD (Eds), Oxford University Press, New York 2001. p.298.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/119\">",
"      Bernstein EF, Spielvogel RL, Topolsky DL. Recurrent neutrophilic eccrine hidradenitis. Br J Dermatol 1992; 127:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/120\">",
"      Beutner KR, Packman CH, Markowitch W. Neutrophilic eccrine hidradenitis associated with Hodgkin's disease and chemotherapy. A case report. Arch Dermatol 1986; 122:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/121\">",
"      Shear NH, Knowles SR, Shapiro L, Poldre P. Dapsone in prevention of recurrent neutrophilic eccrine hidradenitis. J Am Acad Dermatol 1996; 35:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/122\">",
"      Flynn TC, Harrist TJ, Murphy GF, et al. Neutrophilic eccrine hidradenitis: a distinctive rash associated with cytarabine therapy and acute leukemia. J Am Acad Dermatol 1984; 11:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/123\">",
"      B&ouml;ckle BC, Baltaci M, Weyrer W, Sepp NT. Bortezomib-induced lupus erythematosus tumidus. Oncologist 2009; 14:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/124\">",
"      Gerecitano J, Goy A, Wright J, et al. Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response? Br J Haematol 2006; 134:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/125\">",
"      Th&ouml;dtmann R, Sauter T, Weinknecht S, et al. A phase II trial of pemetrexed in patients with metastatic renal cancer. Invest New Drugs 2003; 21:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/126\">",
"      Hughes A, Calvert P, Azzabi A, et al. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol 2002; 20:3533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/127\">",
"      Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/128\">",
"      Scagliotti GV, Shin DM, Kindler HL, et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003; 21:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/129\">",
"      Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21:2636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/130\">",
"      Lopes G, Vincek V, Raez LE. Pemetrexed-associated urticarial vasculitis. Lung Cancer 2006; 51:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/131\">",
"      Eguia B, Ruppert AM, Fillon J, et al. Skin toxicities compromise prolonged pemetrexed treatment. J Thorac Oncol 2011; 6:2083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/132\">",
"      D'Angelo SP, Kris MG, Pietanza MC, et al. A case series of dose-limiting peripheral edema observed in patients treated with pemetrexed. J Thorac Oncol 2011; 6:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/133\">",
"      Grey MR, Flanagan NG, Kelsey PR. Severe skin rash in two consecutive patients treated with 2-chlorodeoxyadenosine for hairy cell leukaemia at a single institution. Clin Lab Haematol 2000; 22:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/134\">",
"      Lee TC, Hook CC, Long HJ. Severe exfoliative dermatitis associated with hand ischemia during cisplatin therapy. Mayo Clin Proc 1994; 69:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/135\">",
"      Bencini PL, Sala F, Crosti C, et al. Exfoliative dermatitis following intravesical therapy with mitomycin C. Int J Dermatol 1985; 24:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/136\">",
"      Peters T, Theile-Ochel S, Chemnitz J, et al. Exfoliative dermatitis after long-term methotrexate treatment of severe psoriasis. Acta Derm Venereol 1999; 79:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/137\">",
"      Kunkeler L, Nieboer C, Bruynzeel DP. Type III and type IV hypersensitivity reactions due to mitomycin C. Contact Dermatitis 2000; 42:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/138\">",
"      Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/139\">",
"      Dissemond J, K&ouml;rber A. Hydroxyurea-induced ulcers on the leg. CMAJ 2009; 180:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/140\">",
"      Sirieix ME, Debure C, Baudot N, et al. Leg ulcers and hydroxyurea: forty-one cases. Arch Dermatol 1999; 135:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/141\">",
"      Weinlich G, Schuler G, Greil R, et al. Leg ulcers associated with long-term hydroxyurea therapy. J Am Acad Dermatol 1998; 39:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/7/36986/abstract/142\">",
"      Best PJ, Daoud MS, Pittelkow MR, Petitt RM. Hydroxyurea-induced leg ulceration in 14 patients. Ann Intern Med 1998; 128:29.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2090 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-DA858D2583-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_7_36986=[""].join("\n");
var outline_f36_7_36986=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25381708\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IMMUNE-MEDIATED HYPERSENSITIVITY REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PIGMENTARY CHANGES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Fluoropyrimidines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Other drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Diffuse reaction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Local",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Serpentine and flagellate hyperpigmentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Hair",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      NAIL DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pigmentary changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Onycholysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Inflammatory changes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PHOTOSENSITIVITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Phototoxic reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Photoallergic reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Photoreactivation and photoenhancement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Photoonycholysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS AND SCLERODERMA-LIKE CHANGES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      RADIATION RECALL AND ENHANCEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Radiation recall dermatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Radiation enhancement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      ACRAL ERYTHEMA (HAND-FOOT SKIN REACTION)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Histology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      NEUTROPHILIC ECCRINE HIDRADENITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      EXANTHEMATOUS ERUPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Exanthematous (morbilliform) rashes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Fixed drug eruptions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Diffuse erythema and exfoliative dermatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Erythema multiforme, SJS, and toxic epidermal necrolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      MISCELLANEOUS REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25381708\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/2090\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/2090|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?14/52/15169\" title=\"picture 1A\">",
"      Beau lines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/10/18592\" title=\"picture 1B\">",
"      Beau line on the toe",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/46/10991\" title=\"picture 2\">",
"      Nail changes docetaxel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/12/11458\" title=\"picture 3A\">",
"      Acral erythema on the hands",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/58/22436\" title=\"picture 3B\">",
"      Acral erythema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/6/37985\" title=\"picture 4A\">",
"      Morbilliform drug eruption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/30/32239\" title=\"picture 4B\">",
"      Morbilliform eruption 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/63/18419\" title=\"picture 5\">",
"      Toxic epidermal necrolysis I",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/2090|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/23/13692\" title=\"table 1\">",
"      Types of allergic reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/43/34492\" title=\"table 2\">",
"      Chemo skin pigment abnl",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/22/34156\" title=\"table 3\">",
"      Chemo nail disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/32/35340\" title=\"table 4\">",
"      Chemotherapy radiation sensitiz",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/11/43195\" title=\"table 5\">",
"      Chemotherapy acral erythema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/45/7900\" title=\"table 6\">",
"      Cutan react multitarg TKI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/20/13643\" title=\"table 7\">",
"      NCI CTCAE grading for palmar plantar erythrodysesthesia syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/29/4571\" title=\"table 8\">",
"      Chemo neut eccrine hidradenitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/7/119\" title=\"table 9\">",
"      Chemotherapy drug eruptions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/2/38956\" title=\"table 10\">",
"      Chemo eryth multiforme SJS TEN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/50/17196\" title=\"table 11\">",
"      Miscell cutaneous tox chemo",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37961?source=related_link\">",
"      Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/12/44232?source=related_link\">",
"      Chemotherapy-induced alopecia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/0/33800?source=related_link\">",
"      Clinical manifestations of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/22/25960?source=related_link\">",
"      Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/25/23962?source=related_link\">",
"      Clinical manifestations, diagnosis, and grading of chronic graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35834?source=related_link\">",
"      Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/18/21802?source=related_link\">",
"      Cutaneous manifestations of internal malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/5/43095?source=related_link\">",
"      Diagnosis and differential diagnosis of systemic sclerosis (scleroderma) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/17/41241?source=related_link\">",
"      Drug eruptions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/50/24360?source=related_link\">",
"      Exanthematous (morbilliform) drug eruption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/13/218?source=related_link\">",
"      Extravasation injury from chemotherapy and other non-neoplastic vesicants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/57/43930?source=related_link\">",
"      Infusion reactions to systemic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/33/36378?source=related_link\">",
"      Mucocutaneous manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/43/30393?source=related_link\">",
"      Neutrophilic dermatoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/22/38250?source=related_link\">",
"      Oral toxicity associated with chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/44/18121?source=related_link\">",
"      Paraneoplastic pemphigus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/40/8842?source=related_link\">",
"      Serum sickness and serum sickness-like reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/29/17882?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/35/36410?source=related_link\">",
"      Treatment of advanced stage (IIB to IV) mycosis fungoides and S&eacute;zary syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_7_36987="Comparison of UIP and DIP";
var content_f36_7_36987=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F65643&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F65643&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of UIP and DIP",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        UIP",
"       </td>",
"       <td class=\"subtitle1\">",
"        DIP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mean age",
"       </td>",
"       <td>",
"        50.9 yrs",
"       </td>",
"       <td>",
"        42.3 yrs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cigarette smokers",
"       </td>",
"       <td>",
"        71 percent",
"       </td>",
"       <td>",
"        90 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Abnormal CXR",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        92.4 percent",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        77.5 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Low volumes",
"       </td>",
"       <td class=\"sublist_other\">",
"        45.0 percent",
"       </td>",
"       <td class=\"sublist_other\">",
"        23.0 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Honeycombing",
"       </td>",
"       <td class=\"sublist_other\">",
"        49.1 percent",
"       </td>",
"       <td class=\"sublist_other\">",
"        12.5 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Mean severity",
"       </td>",
"       <td class=\"sublist_other\">",
"        2/3",
"       </td>",
"       <td class=\"sublist_other\">",
"        1/2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mortality",
"       </td>",
"       <td>",
"        66.0 percent",
"       </td>",
"       <td>",
"        27.5 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mean survival",
"       </td>",
"       <td>",
"        5.6 &plusmn; 3.7 yrs",
"       </td>",
"       <td>",
"        12.2 &plusmn; 5.5 yrs",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data summarized from Carrington, C, Gaensler, E, Coutu, R, et al, N Engl J Med 1978; 298:801.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_7_36987=[""].join("\n");
var outline_f36_7_36987=null;
var title_f36_7_36988="Common IV Solutions A";
var content_f36_7_36988=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F60477&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F60477&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Physiological characteristics and clinical effects of commonly used intravenous solutions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"3\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\" rowspan=\"1\">",
"        Available",
"solutions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">",
"        Albumin",
"solutions",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">",
"        Starches",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        4, 5 percent",
"       </td>",
"       <td class=\"subtitle3\">",
"        20, 25 percent",
"       </td>",
"       <td class=\"subtitle3\">",
"        3, 6, 10 percent Hetastarch",
"       </td>",
"       <td class=\"subtitle3\">",
"        10 percent Pentastarch",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Molecular weight, average (kD)",
"       </td>",
"       <td>",
"        69",
"       </td>",
"       <td>",
"        69",
"       </td>",
"       <td>",
"        450",
"       </td>",
"       <td>",
"        280",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Osmolality, mOsm/L",
"       </td>",
"       <td>",
"        290",
"       </td>",
"       <td>",
"        310",
"       </td>",
"       <td>",
"        300-310",
"       </td>",
"       <td>",
"        326",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        COP, mm Hg",
"       </td>",
"       <td>",
"        20-30",
"       </td>",
"       <td>",
"        70-100",
"       </td>",
"       <td>",
"        23-50",
"       </td>",
"       <td>",
"        23-50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maximum volume expansion,* percent",
"       </td>",
"       <td>",
"        70-100",
"       </td>",
"       <td>",
"        300-500",
"        <br/>",
"       </td>",
"       <td>",
"        100-200",
"       </td>",
"       <td>",
"        100-200",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Duration of volume expansion, h",
"       </td>",
"       <td>",
"        12-24",
"       </td>",
"       <td>",
"        12-24",
"       </td>",
"       <td>",
"        8-36",
"       </td>",
"       <td>",
"        12-24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plasmatic half-life, h",
"       </td>",
"       <td>",
"        16-24",
"       </td>",
"       <td>",
"        16-24",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        2-12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Potential for adverse reactions",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        Possible side effects",
"       </td>",
"       <td>",
"        Allergic reactions",
"       </td>",
"       <td>",
"        Allergic reactions",
"       </td>",
"       <td>",
"        Renal dysfunction",
"       </td>",
"       <td>",
"        Renal dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Transmitted infection",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Transmitted infection",
"       </td>",
"       <td colspan=\"1\">",
"        Coagulopathy",
"       </td>",
"       <td>",
"        Coagulopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pruritus",
"       </td>",
"       <td>",
"        Pruritus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anaphylactoid reactions",
"       </td>",
"       <td>",
"        Anaphylactoid reactions",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     COP: colloid osmotic pressure.",
"     <br>",
"      * Expressed as a percentage of administered volume.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Am J Respir Crit Care Med Vol 170. pp 1247-1259, 2004.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_7_36988=[""].join("\n");
var outline_f36_7_36988=null;
var title_f36_7_36989="Evaluation of pediatric hypernatremia - Uosm and Posm";
var content_f36_7_36989=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F88818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F88818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Utility of urine and plasma osmolality in the evaluation of pediatric hypernatremia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 418px; height: 204px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In cases when the cause of pediatric hypernatremia remains uncertain, comparing the urine osmolality (Uosm) with the plasma osmolality (Posm) may be helpful in establishing the underlying etiology. Uosm that is less than Posm suggests that the&nbsp;child has a concentrating defect, which increases the likelihood of excess urinary water loss. In contrast,&nbsp;children with Uosm greater than Posm have an intact urinary concentrating mechanism and are more likely to have hypernatremia due to excess gastrointestinal or skin water loss, or excess salt intake.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_7_36989=[""].join("\n");
var outline_f36_7_36989=null;
var title_f36_7_36990="Mult sterile corneal infil";
var content_f36_7_36990=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F52402&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F52402&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Multiple sterile corneal infiltrates",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 323px; height: 235px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_7_36990=[""].join("\n");
var outline_f36_7_36990=null;
var title_f36_7_36991="Ultrasound median nerve movement in axial view";
var content_f36_7_36991=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1104px;\">",
"  <div class=\"videoplayer\" h264=\"./images/NEURO/74182/US_med_nerv_move_conv.mp4?title=Ultrasound+median+nerve+movement+in+axial+view\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Ultrasound median nerve movement in axial view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 274px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The axial real-time image of the median nerve (N) is at the level of the distal wrist crease. The video clip captures the normal movement of the median nerve with flexion of the fingers and wrist, as the nerve rotates 90 degrees and dives among the flexor tendons (T). Note that the nerve moves between different tendons with subtle variations in wrist flexion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Francis O Walker, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_7_36991=[""].join("\n");
var outline_f36_7_36991=null;
